Title: Importation of Live Swine (from Certain Regions), Pork, and Pork Products.

OMB Control Number: 0579-0230.

Type of Request: Revision to and extension of approval of an information collection.

Abstract: Under the Animal Health Protection Act (7 U.S.C. 8301 et seq. ), the Animal and Plant Health Inspection Service (APHIS) of the United States Department of Agriculture is authorized, among other things, to prohibit or restrict the importation and interstate movement of animals and animal products to prevent the introduction into and dissemination within the United States of livestock diseases and pests. To carry out this mission, APHIS regulates the importation of animals and animal products into the United States. The regulations for the importation of animals and animal products are contained in 9 CFR parts 92 through 98.

Part 94 allows the importation, under certain conditions, of live swine, pork, and pork products from regions that are free of classical swine fever (CSF) to prevent the introduction of CSF into the United States. Three regions, in Brazil, Chile, and Mexico, are subject to additional restrictions in accordance with §  94.32. APHIS recognizes these regions as free of CSF but restricts importation of live swine, pork, and pork products from these regions because they either supplement their pork supplies by importing fresh (chilled or frozen) pork from CSF-affected regions, supplement their pork supplies with pork from CSF-affected regions that is not processed in accordance with the requirements in part 94, share a common land border with CSF-affected regions, or import live swine from such regions under conditions less restrictive than would be acceptable for importation into the United States.

To ensure that the importation of live swine, pork, and pork products, particularly from Brazil, Chile, and Mexico, do not introduce CSF into the United States, the regulations include information collection activities such as certification for importation of pork or pork products; application of seal; location and reason for breaking seal and application of new seal; termination of agreement; request for approval of defrost facility; request hearing for denial or approval of defrost facility; application for import of small amounts of pork or pork products; cooperative service agreement; notification of Customs and Border Protection inspectors for pork from specific regions; recordkeeping requirements for certificates; certificates for meat processed in tubes; certification for importation of hams; agreement for processing procedures; identification procedures; recordkeeping for processing origin of hams; and program statements.

We are asking OMB to approve our use of these information collection activities, as described, for an additional 3 years. APHIS has amended this information collection by decreasing the number of Respondents, Responses, and Total Burden Hours being reported.

The purpose of this notice is to solicit comments from the public (as well as affected agencies) concerning our information collection. These comments will help us:

(1) Evaluate whether the collection of information is necessary for the proper performance of the functions of the Agency, including whether the information will have practical utility;

(2) Evaluate the accuracy of our estimate of the burden of the collection of information, including the validity of the methodology and assumptions used;

(3) Enhance the quality, utility, and clarity of the information to be collected; and

(4) Minimize the burden of the collection of information on those who are to respond, through use, as appropriate, of automated, electronic, mechanical, and other collection technologies; e.g., permitting electronic submission of responses.

Estimate of burden: The public burden for this collection of information is estimated to average 1.0 hour per response.

Respondents: Full-time, salaried veterinary officers employed by the governments of Chile, Brazil, and Mexico, industry representatives, and U.S. importers.

Estimated annual number of respondents: 772.

Estimated annual number of responses per respondent: 208.

Estimated annual number of responses: 160,388.

Estimated total annual burden on respondents: 160,391 hours. (Due to averaging, the total annual burden hours may not equal the product of the annual number of responses multiplied by the reporting burden per response.)

All responses to this notice will be summarized and included in the request for OMB approval. All comments will also become a matter of public record.

Title: National Animal Health Reporting System and Handling Swine with Potential Vesicular Disease.

OMB Control Number: 0579-0299.

Type of Request: Revision to and extension of approval of an information collection.

Abstract: Under the Animal Health Protection Act (7 U.S.C. 8301 et seq. ), the Animal Plant Health Inspection Service (APHIS) is authorized, among other things, to prohibit or restrict the importation and interstate movement of animals and other articles to prevent the introduction and interstate spread of livestock diseases and to eradicate such diseases from the United States when feasible. In connection with this mission, APHIS operates the National Animal Health Reporting System (NAHRS), which collects, on a national basis, monthly data from State veterinarians on the presence or absence of diseases of interest to the World Organization for Animal Health (WOAH).

As a member country of WOAH, the United States must submit reports to the WOAH on the status of certain diseases in specific livestock, poultry, and aquaculture species. Reportable diseases are diseases that have the potential for rapid spread, irrespective of national borders, that are of serious socioeconomic or public health consequence, and that are of major importance in the international trade of animals and animal products. The potential benefits to trade of accurate reporting on the health status of the U.S. commercial livestock, poultry, and aquaculture industries include expansion of those industries into new export markets and preservation of existing markets through increased confidence in quality and disease freedom. This data collection is unique in terms of the type, quantity, and frequency because no other entity is collecting and reporting data to the WOAH on the health status of U.S. livestock, poultry, and aquaculture.

Information collected from the States covers the monthly NAHRS 1 reports. The NAHRS 2 and NVSL 201 burden, which were added to the previous renewal of this collection and were used to report on emerging diseases and SARS-CoV-2 testing in animals, are no longer being used and have been removed from this collection (0579-0299).

VS' mission also includes preventing foreign animal disease outbreaks in the United States, and monitoring, controlling, and eliminating a disease outbreak should one occur. Any swine having vesicular lesions are suspects for foreign animal diseases (FADs), such as foot-and-mouth disease (FMD), until determined otherwise by VS through authorized testing at approved National Animal Health Laboratory Network (NAHLN) laboratories with oversight and confirmatory testing, if required, by the Foreign Animal Disease Diagnostic Laboratory (FADDL). Several viral pathogens may cause vesicular lesions in swine, including FMD virus, swine vesicular disease virus, vesicular stomatitis virus, and Senecavalley A virus. Veterinarians are unable to differentiate the etiology of these gross lesions without diagnostic testing. Vesicular lesions on swine should be reported by State, Federal, and accredited veterinarians to ensure rapid detection of FMD or any other FAD, if introduced. This is done to protect the health, public confidence, and marketability of our nation's livestock health, marketability of meat products, and public confidence. Information collection includes notifiable swine disease reporting, NAHRS monthly State and Area Veterinarian In Charge (AVIC) reports, and FAD data collection and investigations. These information collection activities have been approved by the Office of Management and Budget (OMB) under control number 0579-0493.

The information collection activities currently reported under OMB number 0579-0493 (Handling Swine with Potential Vesicular Disease) is being merged into this collection (0579-0299). After OMB approves and combines the burden for both collections under 0579-0299, 0579-0493 will be discontinued.

We are asking OMB to approve our use of these information collection activities, as described, for 3 years.

The purpose of this notice is to solicit comments from the public (as well as affected agencies) concerning our information collection. These comments will help us:

(1) Evaluate whether the collection of information is necessary for the proper performance of the functions of the Agency, including whether the information will have practical utility;

(2) Evaluate the accuracy of our estimate of the burden of the collection of information, including the validity of the methodology and assumptions used;

(3) Enhance the quality, utility, and clarity of the information to be collected; and

(4) Minimize the burden of the collection of information on those who are to respond, through use, as appropriate, of automated, electronic, mechanical, and other collection technologies; e.g., permitting electronic submission of responses.

Estimate of burden: The public burden for this collection of information is estimated to average 1.75 hours per response.

Respondents: State veterinarians, farmers, public health officials, and animal scientists.

Estimated annual number of respondents: 172.

Estimated annual number of responses per respondent: 44.

Estimated annual number of responses: 7,524.

Estimated total annual burden on respondents: 13,167 hours. (Due to averaging, the total annual burden hours may not equal the product of the annual number of responses multiplied by the reporting burden per response.)

All responses to this notice will be summarized and included in the request for OMB approval. All comments will also become a matter of public record.

These programs are located in the Assistance Listings under Nos. 10.555 and 10.558 and are subject to the provisions of Executive Order 12372, which requires intergovernmental consultation with State and local officials. (See 7 CFR part 3015, subpart V, and final rule related notice published at 48 FR 29114, June 24, 1983.)

This notice imposes no new reporting or recordkeeping provisions that are subject to Office of Management and Budget review in accordance with the Paperwork Reduction Act of 1995 (44 U.S.C. 3507). This action is not a rule as defined by the Regulatory Flexibility Act (5 U.S.C. 601-612) and thus is exempt from the provisions of that Act. This notice was reviewed by the Office of Management and Budget under Executive Order 12866. Pursuant to the Congressional Review Act (5 U.S.C. 801 et seq. ), the Office of Information and Regulatory Affairs designated this rule as not a major rule, as defined by 5 U.S.C. 804(2).

This notice implements mandatory provisions of sections 6(c) and 17(h)(1)(B) of the Richard B. Russell National School Lunch Act (the Act) (42 U.S.C. 1755(c) and 1766(h)(1)(B)). Section 6(c)(1)(A) of the Act establishes the national average value of donated food assistance to be given to States for each lunch served in the NSLP at 11.00 cents per meal. Pursuant to section 6(c)(1)(B), this amount is subject to annual adjustments on July 1 of each year to reflect changes in a three-month average value of the Producer Price Index for Foods Used in Schools and Institutions for March, April, and May each year (Price Index). Section 17(h)(1)(B) of the Act provides that the same value of donated foods (or cash in lieu of donated foods) for school lunches shall also be established for lunches and suppers served in the CACFP. Notice is hereby given that the national average minimum value of donated foods, or cash in lieu thereof, per lunch under the NSLP (7 CFR part 210) and per lunch and supper under the CACFP (7 CFR part 226) shall be 32.00 cents for the period July 1, 2026 through June 30, 2027.

The Price Index is computed using five major food components in the Bureau of Labor Statistics Producer Price Index (cereal and bakery products; meats, poultry, and fish; dairy; processed fruits and vegetables; and fats and oils). Each component is weighted using the relative weight as determined by the Bureau of Labor Statistics. The value of food assistance is adjusted each July 1 by the annual percentage change in a three-month average value of the Price Index for March, April, and May each year. The three-month average of the Price Index increased by 4.65 percent from 267.65 for March, April, and May of 2025 as previously published in the Federal Register , to 280.09 for the same three months in 2026. When computed on the basis of unrounded data and rounded to the nearest one-quarter cent, the resulting national average for the period July 1, 2026 through June 30, 2027 will be 32.00 cents per meal. This is an increase of one and a half cents from the school year 2026 (July 1, 2025 through June 30, 2026) rate.

Authority: Sections 6(c)(1)(A) and (B), 6(e)(1), and 17(h)(1)(B) of the Richard B. Russell National School Lunch Act (42 U.S.C. 1755(c)(1)(A) and (B) and (e)(1), and 1766(h)(1)(B)).

The provisions of paragraph (a)(i) of the Additional U.S. Note 5, Chapter 17 in the U.S. Harmonized Tariff Schedule (HTS) authorize the Secretary to establish the in-quota tariff-rate quota (TRQ) amounts (expressed in terms of raw value) for imports of raw cane sugar and certain sugars, syrups, and molasses that may be entered under the subheadings of the HTS subject to the lower tier of duties during each fiscal year. The Office of the U.S. Trade Representative (USTR) is responsible for the allocation of these quantities among supplying countries and areas. Section 359k of the Agricultural Adjustment Act of 1938, as amended, requires that at the beginning of the quota year the Secretary of Agriculture establish the TRQs for raw cane sugar and refined sugars at the minimum levels necessary to comply with obligations under international trade agreements, with the exception of specialty sugar.

The Secretary's authority under paragraph (a)(i) of the Additional U.S. Note 5, Chapter 17 in the HTS and Section 359k of the Agricultural Adjustment Act of 1938, as amended, has been delegated to the Under Secretary for Trade and Foreign Agricultural Affairs (7 CFR 2.15). The Under Secretary has subsequently delegated this authority to the Administrator, Foreign Agricultural Service (7 CFR 2.601).

Notice is hereby given that I have determined, in accordance with paragraph (a)(i) of the Additional U.S. Note 5, Chapter 17 in the HTS and section 359k of the 1938 Act, that an aggregate quantity of up to 1,117,195 MTRV of raw cane sugar may be entered or withdrawn from warehouse for consumption during FY 2027. This is the minimum amount to which the United States is committed under the WTO Uruguay Round Agreements. The conversion factor is 1 metric ton raw value equals 1.10231125 short tons raw value. USTR will allocate these quantities among supplying countries and customs areas.

I have further determined that an aggregate quantity of 22,000 MTRV of sugars, syrups, and molasses (refined sugar) may be entered or withdrawn from warehouse for consumption during FY 2027. This quantity includes the minimum amount to which the United States is committed under the WTO Uruguay Round Agreements, 22,000 MTRV, of which 20,344 MTRV is established for any sugars, syrups and molasses, and 1,656 MTRV is reserved for specialty sugar. No additional amount is added to the specialty sugar TRQ.

The FY 2027 specialty sugar TRQ will be opened on a first-come, first-served basis on October 1, 2026.

These Committee meetings are available to the public through the registration links above. Any interested members of the public may attend these meetings. Open comment periods for each meeting will be provided to allow members of the public to make oral comments as time allows. Pursuant to the Federal Advisory Committee Act, public minutes of meetings will include list of persons who are present at the meetings. If joining via phone, callers can expect to incur regular charges for calls they initiate over wireless lines, according to their wireless plan. The Commission will not refund any incurred charges. Callers will incur no charge for calls they initiate over land-line connections to the toll-free telephone number. Closed captioning is available by selecting “CC” in the meeting platforms. To request accommodations, please email ebohor@usccr.gov at least 10 business days prior to the meetings.

Members of the public are entitled to submit written comments; the comments must be received in the regional office within 30 days following scheduled meetings. Written comments may be submitted via: https://tinyurl.com/mvtxewfe. Persons who desire additional information may contact the Regional Programs Coordination Unit at 1-202-809-9618.

Records generated from meetings may be inspected and reproduced at the Regional Programs Coordination Unit Office, as they become available, both before and after each meeting. Records of the meetings will be available via the file sharing website, https://tinyurl.com/28867tbx. Persons interested in the work of this Committee are directed to the Commission's website, http://www.usccr.gov, or may contact the Regional Programs Coordination Unit at mtrachtenberg@usccr.gov.

Committee meetings are available to the public through the registration links above. Any interested members of the public may attend committee meetings. Open comment periods will be provided at each meeting to allow members of the public to make oral statements as time allows. Pursuant to the Federal Advisory Committee Act, public minutes of meetings will include a list of persons who are present at meetings. If joining via phone, callers can expect to incur regular charges for calls they initiate over wireless lines, according to their wireless plan. The Commission will not refund any incurred charges. Callers will incur no charge for calls they initiate over land-line connections to the toll-free telephone number. Closed captioning is available by selecting “CC” in the meeting platform. To request accommodations, please email ebohor@usccr.gov at least 10 business days prior to the meetings.

Members of the public are entitled to submit written comments; the comments must be received in the regional office within 30 days following the scheduled meetings. Written comments may be submitted via the following form: https://wkf.ms/4wEILYL. Persons who desire additional information may contact the Regional Programs Coordination Unit at (202) 809-9618.

Records generated from meetings may be inspected and reproduced at the Regional Programs Coordination Unit Office, as they become available, both before and after meetings. Records of meetings will be available via the file sharing website, https://bit.ly/42t1cCA. Persons interested in the work of this Committee are directed to the Commission's website, http://www.usccr.gov, or may contact the Regional Programs Coordination Unit at mtrachtenberg@usccr.gov.

This Committee meeting is available to the public through the registration link above. Any interested members of the public may attend this meeting. An open comment period will be provided to allow members of the public to make oral comments as time allows. Pursuant to the Federal Advisory Committee Act, public minutes of the meeting will include a list of persons who are present at the meeting. If joining via phone, callers can expect to incur regular charges for calls they initiate over wireless lines, according to their wireless plan. The Commission will not refund any incurred charges. Callers will incur no charge for calls they initiate over land-line connections to the toll-free telephone number. Closed captioning is available by selecting “CC” in the meeting platform. To request accommodations, please email ebohor@usccr.gov at least 10 business days prior to the meeting.

Members of the public are entitled to submit written comments; the comments must be received in the regional office within 30 days following the scheduled meeting. Written comments may be emailed to Mallory Trachtenberg at https://tinyurl.com/4fjtwv3h. Persons who desire additional information may contact the Regional Programs Coordination Unit at (202) 809-9618.

Records generated from this meeting may be inspected and reproduced at the Regional Programs Coordination Unit Office, as they become available, both before and after the meeting. Records of the meetings will be available via the file sharing website, https://bit.ly/3ZzHlj5. Persons interested in the work of this Committee are directed to the Commission's website, http://www.usccr.gov, or may contact the Regional Programs Coordination Unit at mtrachtenberg@usccr.gov.

On May 20, 2025, based on timely requests for review, in accordance with 19 CFR 351.221(c)(1)(i), we initiated an administrative review of the countervailing duty order on aluminum sheet from India. 1 On June 26, 2025, the petitioners  2 timely withdrew their requests for review of Hindalco Industries Limited (Hindalco), Jindal Aluminum Limited (Jindal), and Virgo Aluminum Limited (Virgo). 3

Due to a lapse in appropriations and Federal Government shutdown, on November 14, 2025, Commerce tolled all deadlines in administrative proceedings by 47 days. 4 Due to a backlog of documents that were electronically filed via Enforcement and Compliance's Antidumping and Countervailing Duty Centralized Electronic Service System (ACCESS) during the Federal Government shutdown, on November 24, 2025, Commerce tolled all deadlines in administrative proceedings by an additional 21 days. 5 Additionally, on March 3, 2026, we extended the deadline for the preliminary results until June 30, 2026. 6 On June 29, 2026, we extended the deadline for the preliminary results until July 7, 2026. 7

For a complete description of the events that followed the initiation of this review, see the Preliminary Decision Memorandum. 8 A list of topics discussed in the Preliminary Decision Memorandum is included in an appendix to this notice. The Preliminary Decision Memorandum is a public document and is on file electronically via ACCESS. ACCESS is available to registered users at https://access.trade.gov. In addition, a complete version of the Preliminary Decision Memorandum can be accessed directly at https://access.trade.gov/frnotices.

The merchandise covered by this Order is aluminum sheet from India. For a complete description of the scope of the Order, see the Preliminary Decision Memorandum.

Pursuant to 19 CFR 351.213(d)(1), Commerce will rescind an administrative review, in whole or in part, if the party that requested a review withdraws the request within 90 days of the date of the publication of the notice of initiation. As noted above, Commerce received timely-filed withdrawal requests with respect to Hindalco, Jindal, and Virgo and no other parties requested a review of these companies. Therefore, we are rescinding this administrative review with respect to Hindalco, Jindal, and Virgo, pursuant to 19 CFR 351.213(d)(1).

Commerce is conducting this review in accordance with section 751(a)(1)(A) of the Tariff Act of 1930, as amended (the Act). For each of the subsidy programs found countervailable, Commerce preliminarily determines that there is a subsidy, i.e., a financial contribution by an “authority” that gives rise to a benefit to the recipient, and that the subsidy is specific. 9 For a full description of the methodology underlying our preliminary conclusions, see the Preliminary Decision Memorandum.

As a result of this review, we preliminarily determine the following net countervailable subsidy rate exists for the period January 1, 2024, through December 31, 2024:

Commerce intends to disclose its calculations performed to interested parties for these preliminary results within 10 days of any public announcement or, if there is no public announcement, within five days of the date of publication of this notice in the Federal Register in accordance with 19 CFR 351.224(b).

On August 20, 2025, the petitioners requested that Commerce conduct verification of MALCO's responses. 10 Accordingly, in May 2026, as provided in section 782(i)(3) of the Act, we verified MALCO's information relied upon for the preliminary results of this review. 11

Case briefs or other written comments may be submitted to the Assistant Secretary for Enforcement and Compliance no later than seven days after the date on which Commerce issues its post-preliminary analysis in this administrative review. Rebuttal briefs, limited to issues raised in the case briefs, may be filed no later than five days after the date for filing case briefs. 12 Interested parties who submit case or rebuttal briefs in this proceeding must submit: (1) a table of contents listing each issue; and (2) a table of authorities. 13 All briefs must be filed electronically using ACCESS. An electronically-filed document must be received successfully in its entirety by ACCESS by 5:00 p.m. Eastern Time on the established deadline.

As provided under 19 CFR 351.309(c)(2) and (d)(2), in prior proceedings we have encouraged interested parties to provide an executive summary of their brief that should be limited to five pages total, including footnotes. 14 Further, we request that interested parties limit their public executive summary of each issue to no more than 450 words, not including citations. We intend to use the public executive summaries as the basis of the comment summaries included in the issues and decision memorandum that will accompany the final results in this administrative review. We request that interested parties include footnotes for relevant citations in the public executive summary of each issue. Note that Commerce has amended certain of its requirements pertaining to the service of documents in 19 CFR 351.303(f). 15

Pursuant to 19 CFR 351.310(c), interested parties who wish to request a hearing must submit a written request to the Assistant Secretary for Enforcement and Compliance, filed electronically via ACCESS by 5:00 p.m. Eastern Time within 30 days after the date of publication of this notice. Requests should contain: (1) the party's name, address, and telephone number; (2) the number of participants; and (3) a list of issues to be discussed. Oral presentations at the hearing will be limited to issues raised in the case briefs. If a request for a hearing is made, Commerce will inform parties of the scheduled date for the hearing. 16

Consistent with section 751(a)(1) of the Act and 19 CFR 351.212(b)(2), upon issuance of the final results, Commerce shall determine, and CBP shall assess, countervailing duties on all appropriate entries covered by this review.

For the companies listed above for which the review is being rescinded, Commerce will instruct CBP to assess countervailing duties on all appropriate entries at a rate equal to the cash deposit of estimated countervailing duties required at the time of entry, or withdrawal from warehouse, for consumption, in accordance with 19 CFR 351.212(c)(l)(i). Commerce intends to issue these rescission instructions to CBP no earlier than 35 days after the date of publication of this notice in the Federal Register .

Commerce intends to issue assessment instructions to CBP regarding MALCO no earlier than 35 days after the date of publication of the final results of this review in the Federal Register . If a timely summons is filed at the U.S. Court of International Trade, the assessment instructions will direct CBP not to liquidate relevant entries until the time for parties to file a request for a statutory injunction has expired ( i.e., within 90 days of publication).

Pursuant to section 751(a)(2)(C) of the Act and 19 CFR 351.107(e), Commerce intends to instruct CBP to collect cash deposits of estimated countervailing duties with regard to shipments of subject merchandise entered, or withdrawn from warehouse, for consumption on or after the date of publication of the final results of this review, as follows: (1) the cash deposit rate for the company listed above will be equal to the company-specific estimated individual countervailable subsidy rate determined in the final results of this review, except if the rate is less than 0.50 percent and, therefore, de minimis within the meaning of 19 CFR 351.106(c)(1), in which case the cash deposit rate will be zero; (2) if both the producer and exporter of the subject merchandise have company-specific estimated subsidy rates assigned, and their rates differ, then the applicable cash deposit rate will be the higher of these two rates; (3) if either the producer or the exporter, but not both, of the subject merchandise has a company-specific estimated subsidy rate assigned, the applicable cash deposit rate will be that company's company-specific rate; and (4) the cash deposit rate for all other producers and exporters will be continue to be 30.15 percent, the all-others subsidy rate established in the investigation. 17 These cash deposit instructions, when imposed, shall remain in effect until further notice.

Unless extended, Commerce intends to issue the final results of this administrative review, which will include the results of Commerce's analysis of the issues raised in the case briefs, within 120 days of publication of these preliminary results in the Federal Register , pursuant to section 751(a)(3)(A) of the Act and 19 CFR 351.213(h).

We are issuing and publishing these preliminary results in accordance with sections 751(a)(1) and 777(i)(1) of the Act, and 19 CFR 351.221(b)(4).

On March 17, 2026, the U.S. Department of Commerce (Commerce) initiated a less-than-fair-value (LTFV) investigation of imports of truck bed covers from the People's Republic of China. 1 Currently, the preliminary determination is due no later than August 4, 2026.

Section 733(b)(l)(A) of the Tariff Act of 1930, as amended (the Act), requires Commerce to issue the preliminary determination in a LTFV investigation within 140 days after the date on which Commerce initiated the investigation. However, if Commerce concludes that the parties concerned in the investigations are cooperating and determines that the investigation is extraordinarily complicated, sections 733(c)(1)(B)(i) and (ii) of the Act allows Commerce to postpone the preliminary determination until no later than 190 days after the date on which Commerce initiated the investigation.

Commerce has determined that the parties involved in the proceeding are cooperating and that the investigation is extraordinarily complicated. 2 Specifically, Commerce requires additional time to analyze the separate rate applications, analyze the questionnaire responses, and issue appropriate requests for clarification and additional information. Therefore, in accordance with section 733(c)(1)(B) of the Act, Commerceis postponing the deadline for issuing the preliminary determination of this investigation by 50 days.

As a result, Commerce will issue its preliminary determination no later than September 23, 2026. Pursuant to section 735(a)(l) of the Act and 19 CFR 351.210(b)(1), the deadline for the final determinations will continue to be 75 days after the date of the preliminary determinations, unless postponed at a later date.

This notice is issued and published pursuant to section 733(c)(2) of the Act and 19 CFR 351.205(f)(1).

On January 9, 2026, Commerce published the Preliminary Results of this administrative review and we invited interested parties to comment. 1 A summary of the events that occurred since Commerce published the Preliminary Results, as well as a full discussion of the issues raised by parties for these final results, are discussed in the Issues and Decision Memorandum. 2

The Issues and Decision Memorandum is a public document and is on-file electronically via Enforcement and Compliance's Antidumping and Countervailing Duty Centralized Electronic Service System (ACCESS), which is available to registered users at https://access.trade.gov. In addition, a complete version of the Issues and Decision Memorandum can be accessed directly at https://access.trade.gov/frnotices.

The product covered by this Order is steel nails from Oman. For a complete description of the scope of the Order, see the Issues and Decision Memorandum.

All issues raised in the parties' case and rebuttal briefs are addressed in the Issues and Decision Memorandum and are listed in the appendix to this notice.

Based on comments received from interested parties regarding our Preliminary Results and our review of the record, we made changes to the preliminary weighted-average dumping margin calculations for Oman Fasteners, as detailed in the Issues and Decision Memorandum. 4

As a result of this review, we determine the following estimated weighted-average dumping margin exists for the POR:

Commerce intends to disclose the calculations and analysis performed for these final results to interested parties within five days of any public announcement or, if there is no public announcement, within five days of the date of publication of this notice in the Federal Register , in accordance with 19 CFR 351.224(b).

Commerce has determined, and U.S. Customs and Border Protection (CBP) shall assess, antidumping duties on all appropriate entries of subject merchandise in accordance with these final results of review. 5 Pursuant to 19 CFR 351.212(b)(1), we calculated importer-specific ad valorem duty assessment rates based on the ratio of the total amount of dumping calculated for the examined sales to the total entered value of the sales for which entered value was reported. Where the respondent's weighted-average dumping margin is zero or de minimis within the meaning of 19 CFR 351.106(c)(1), or an importer-specific assessment rate is zero or de minimis, we will instruct CBP to liquidate the appropriate entries without regard to antidumping duties.

Commerce's “automatic assessment” practice will apply to entries of subject merchandise during the POR produced by companies included in these final results of review for which the reviewed companies did not know that the merchandise it sold to the intermediary ( e.g., a reseller, trading company, or exporter) was destined for the United States. In such instances, we will instruct CBP to liquidate unreviewed entries at the all-others rate if there is no rate for the intermediate company(ies) involved in the transaction. 6

Commerce intends to issue assessment instructions to CBP no earlier than 35 days after the date of publication of the final results of this review in the Federal Register . If a timely summons is filed at the U.S. Court of International Trade, the assessment instructions will direct CBP not to liquidate relevant entries until the time for parties to file a request for a statutory injunction has expired ( i.e., within 90 days of publication).

The following deposit requirements will be effective for all shipments of the subject merchandise entered, or withdrawn from warehouse, for consumption on or after the publication date of the final results of this administrative review, as provided by section 751(a)(2)(C) of the of the Tariff Act of 1930, as amended (Act): (1) the cash deposit rate for the companies listed above will be equal to the weighted-average dumping margin that is established in the “Final Results of Review”; (2) for previously investigated or reviewed companies not subject to this review, the cash deposit rate will continue to be the company-specific rate published for the most recently completed segment of this proceeding in which the company participated; (3) if the exporter is not a firm covered in this review, a prior review, or the original less-than-fair-value (LTFV) investigation, but the producer is, the cash deposit rate will be the rate established for the most recently completed segment of the proceeding for the producer of the merchandise; and (4) the cash deposit rate for all other producers and exporters will continue to be 9.10 percent ad valorem, the all-others rate established in the LTFV investigation. 7 These cash deposit requirements, when imposed, shall remain in effect until further notice.

This notice also serves as a final reminder to importers of their responsibility under 19 CFR 351.402(f)(2) to file a certificate regarding the reimbursement of antidumping duties prior to liquidation of the relevant entries during the POR. Failure to comply with this requirement could result in Commerce's presumption that reimbursement of antidumping duties occurred and the subsequent assessment of double antidumping duties.

This notice also serves as a reminder to parties subject to an administrative protective order (APO) of their responsibility concerning the return or destruction of proprietary information disclosed under APO in accordance with 19 CFR 351.305(a)(3), which continues to govern business proprietary information in this segment of the proceeding. Timely written notification of the return or destruction of APO materials, or conversion to judicial protective order, is hereby requested. Failure to comply with the regulations and the terms of an APO is a sanctionable violation.

We are issuing and publishing this notice in accordance with sections 751(a)(1) and 777(i)(1) of the Act, and 19 CFR 351.221(b)(5) and 19 CFR 351.213(h)(1).

On May 10, 2012, we published the antidumping duty order on stilbenic OBAs from Taiwan in the Federal Register . 1 On June 25, 2025, based on timely requests for an administrative review, in accordance with 19 CFR 351.221(c)(1)(i), we initiated this administrative review of the Order with respect to TFM. 2

Due to the lapse in appropriations and Federal Government shutdown, on November 14, 2025, Commerce tolled all deadlines in administrative proceedings by 47 days. 3 Additionally, due to a backlog of documents that were electronically filed via Enforcement and Compliance's Antidumping and Countervailing Duty Centralized Electronic Service System (ACCESS) during the Federal Government shutdown, on November 24, 2025, Commerce tolled all deadlines in administrative proceedings by an additional 21 days. 4 On March 12 and June 3, 2026, Commerce extended the deadline for the preliminary results by 60 days and 30 days, respectively. 5 Accordingly, the deadline for these preliminary results is now July 8, 2026.

For a complete description of the events that followed the initiation of this review, see the Preliminary Decision Memorandum. 6 A list of the topics discussed in the Preliminary Decision Memorandum is attached as an appendix to this notice. The Preliminary Decision Memorandum is a public document and is on file electronically via ACCESS, which is available to registered users at https://access.trade.gov. In addition, a complete version of the Preliminary Decision Memorandum is available at https://access.trade.gov/frnotices.

The products covered by the Order are stilbenic OBAs from Taiwan. For a complete description of the scope of the Order, see the Preliminary Decision Memorandum.

Commerce is conducting this review in accordance with sections 751(a)(1)(B) and (2) of the Tariff Act of 1930, as amended (the Act). Export price and constructed export price are calculated in accordance with section 772 of the Act. NV is calculated in accordance with section 773 of the Act. For a full description of the methodology underlying these preliminary results, see the Preliminary Decision Memorandum.

As a result of this review, we preliminarily determine that the following weighted-average dumping margin exists for the POR May 1, 2024, through April 30, 2025:

Commerce intends to disclose the calculations and analysis performed to interested parties for these preliminary results within 10 days after public announcement, or if there is no public announcement, within five days of the date of publication of this notice in the Federal Register in accordance with 19 CFR 351.224(b).

Case briefs or other written comments may be submitted to the Assistant Secretary for Enforcement and Compliance. Pursuant to 19 CFR 351.309(c)(1)(ii), we have modified the deadline for interested parties to submit case briefs to Commerce to no later than 21 days after the date of the publication of this notice. 7 Rebuttal briefs, limited to issues raised in the case briefs, may be filed not later than five days after the date for filing case briefs. 8 Interested parties who submit case or rebuttal briefs in this proceeding must submit: (1) a table of contents listing each issue; and (2) a table of authorities. 9 All briefs must be filed electronically using ACCESS. An electronically filed document must be received successfully in its entirety in ACCESS by 5:00 p.m. Eastern Time on the established deadline.

As provided under 19 CFR 351.309(c)(2)(iii) and (d)(2)(iii), we request that interested parties provide at the beginning of their briefs a public executive summary for each issue raised in their briefs. 10 Further, we request that interested parties limit their public executive summary of each issue to no more than 450 words, not including citations. We intend to use the public executive summaries as the basis of the comment summaries included in the issues and decision memorandum that will accompany the final results in this administrative review. We request that interested parties include footnotes for relevant citations in the executive summary of each issue. Note that Commerce has amended certain requirements pertaining to the service of documents in 19 CFR 351.303(f). 11

Pursuant to 19 CFR 351.310(c), interested parties who wish to request a hearing, must submit a written request to the Assistant Secretary for Enforcement and Compliance, filed electronically via ACCESS by 5:00 p.m. Eastern Time within 30 days after the date of publication of this notice. Requests should contain: (1) the party's name, address, and telephone number; (2) the number of participants, and whether any participant is a foreign national; and (3) a list of the issues to be discussed. Oral presentations at the hearing will be limited to issues raised in the briefs. If a request for a hearing is made, Commerce will inform parties of the scheduled date for the hearing. 12

Commerce intends to issue the final results of this administrative review, including the results of its analysis of the issues raised in any written briefs, no later than 120 days after the date of publication of these preliminary results in the Federal Register , unless extended, pursuant to section 751(a)(3)(A) of the Act and 19 CFR 351.213(h)(1).

Pursuant to section 751(a)(2)(A) of the Act and 19 CFR 351.212(b)(1), Commerce will determine, and U.S. Customs and Border Protection (CBP) shall assess, antidumping duties on all appropriate entries of subject merchandise in accordance with the final results of this review. 13

If TFM's weighted-average dumping margin is not zero or de minimis ( i.e., less than 0.50 percent) in the final results of this review, Commerce intends to calculate an importer-specific assessment rate based on the ratio of the total amount of dumping calculated for each importer's examined sales to the total entered value of those sales. Where we do not have entered values for all U.S. sales to a particular importer, we will calculate an importer-specific, per-unit assessment rate on the basis of the ratio of the total amount of dumping calculated for the importer's examined sales to the total quantity of those sales. 14 To determine whether an importer-specific, per-unit assessment rate is de minimis, in accordance with 19 CFR 351.106(c)(2), we also will calculate an importer-specific ad valorem ratio based on estimated entered values. If TFM's weighted-average dumping margin s zero or de minimis or where an importer-specific ad valorem assessment rate is zero or de minimis, we will instruct CBP to liquidate appropriate entries without regard to antidumping duties. 15

In accordance with Commerce's “automatic assessment” practice, for entries of subject merchandise during the POR produced by TFM for which it did not know that the merchandise was destined for the United States, we intend to instruct CBP to liquidate those entries at the all-others rate calculated in the less-than-fair-value (LTFV) investigation if there is no rate for the intermediate company(ies) involved in the transaction. 16

Commerce intends to issue assessment instructions to CBP no earlier than 35 days after the date of publication of the final results of this review in the Federal Register . 17 If a timely summons is filed at the U.S. Court of International Trade, the assessment instructions will direct CBP not to liquidate relevant entries until the time for parties to file a request for a statutory injunction has expired ( i.e., within 90 days of publication).

The following cash deposit requirements will be effective for all shipments of the subject merchandise entered, or withdrawn from warehouse, for consumption on or after the date of publication of the final results of this administrative review, 18 as provided by section 751(a)(2)(C) of the Act: (1) the cash deposit rate for TFM will be that established in the final results of this review, except if the rate is less than 0.50 percent and, therefore, de minimis within the meaning of 19 CFR 351.106(c)(1), in which case the cash deposit rate will be zero; (2) for previously investigated or reviewed companies not covered by this review, the cash deposit rate will continue to be the company-specific cash deposit rate published for the most recently completed segment of this proceeding in which the company participated; (3) if the exporter is not a firm covered in this review, or the LTFV investigation, but the manufacturer is, then the cash deposit rate will be the rate established for the most recent segment for the manufacturer of the merchandise; and (4) the cash deposit rate for all other manufacturers or exporters will continue to be 6.19 percent, the all-others rate established in the LTFV investigation. 19 These cash deposit requirements, when imposed, shall remain in effect until further notice.

This notice serves as a preliminary reminder to importers of their responsibility under 19 CFR 351.402(f)(2) to file a certificate regarding the reimbursement of antidumping duties prior to liquidation of the relevant entries during this review period. Failure to comply with this requirement could result in Commerce's presumption that reimbursement of antidumping duties occurred and the subsequent assessment of double antidumping duties.

We are issuing and publishing these preliminary results of review in accordance with sections 751(a)(1) and 777(i) of the Act and 19 CFR 351.221(b)(4).

Authority: The CAFTA-DR; Section 203(o)(4) of the Dominican Republic-Central America-United States Free Trade Agreement Implementation Act (“CAFTA-DR Implementation Act”), Public Law 109-53; the Statement of Administrative Action accompanying the CAFTA-DR Implementation Act; and Presidential Proclamation 7987 (February 28, 2006).

Background: The CAFTA-DR provides a list in Annex 3.25 for fabrics, yarns, and fibers that the Parties to the CAFTA-DR have determined are not available in commercial quantities in a timely manner in the territory of any Party. The CAFTA-DR provides that this list may be modified pursuant to Article 3.25.4, when the United States determines that a fabric, yarn, or fiber is not available in commercial quantities in a timely manner in the territory of any Party. See Annex 3.25 of the CAFTA-DR; see also section 203(o)(4)(C) of the CAFTA-DR Implementation Act.

The CAFTA-DR Implementation Act requires the President to establish procedures governing the submission of a request and providing opportunity for interested entities to submit comments and supporting evidence before a commercial availability determination is made. In Presidential Proclamation 7987, the President delegated to CITA the authority under section 203(o)(4) of CAFTA-DR Implementation Act for modifying the Annex 3.25 list. Pursuant to this authority, on September 15, 2008, CITA published modified procedures it would follow in considering requests to modify the Annex 3.25 list of products determined to be not commercially available in the territory of any Party to the CAFTA-DR ( Modifications to Procedures for Considering Requests Under the Commercial Availability Provision of the Dominican Republic-Central America-United States Free Trade Agreement, 73 FR 53200) (“CITA's Procedures”).

On May 11, 2026, CITA received a Commercial Availability Request (“Request”) from VARSITY PRO LTDA DE C.V. (“Varsity”) for certain double weave polyester/spandex fabric, as specified below. On May 13, 2026, in accordance with CITA's Procedures, CITA notified interested parties of the Request, which was posted on the dedicated website for CAFTA-DR Commercial Availability proceedings. In its notification, CITA advised that any Response with an Offer to Supply (“Response”) must be submitted by May 26, 2026, and any Rebuttal to a Response (“Rebuttal”) must be submitted by June 1, 2026, in accordance with sections 6 and 7 of CITA's Procedures.

On May 26, 2026, Summitex Woven Textiles (“Summitex”) submitted a response to the pending request. On June 1, 2026, Varsity submitted a rebuttal to Summitex's response. In accordance with section 203(o)(4) of the CAFTA-DR Implementation Act, Article 3.25 of the CAFTA-DR, and section 8(c)(4) of CITA's procedures, because there was insufficient information on the record to make a determination within 30 business days, CITA extended the period to make a determination by 14 U.S. business days. Further, in accordance with section 8(c)(4)(i) of its procedures, CITA called for a public meeting on June 11, 2026 with representatives of Varsity and Summitex to provide the companies with an opportunity to submit additional evidence to substantiate their claims regarding Summitex's capability to supply the subject product in commercial quantities in a timely manner.

Section 203(o)(4)(C)(ii) of the CAFTA-DR Implementation Act provides that after receiving a request, a determination will be made as to whether the subject product is available in commercial quantities in a timely manner in the CAFTA-DR countries. In the instant case, the information on the record indicates that Varsity made significant efforts to source the fabric in the CAFTA-DR region, specifically from Summitex. However, Summitex has not demonstrated its ability to supply the subject product in commercial quantities in a timely manner. Therefore, in accordance with section 203(o) of the CAFTA-DR Implementation Act and CITA's procedures, as no interested entity has substantiated its ability to supply the subject product in commercial quantities in a timely manner, CITA has determined to add the specified fabric to the list in Annex 3.25 of the CAFTA-DR.

The subject product has been added to the list in Annex 3.25 of the CAFTA-DR Agreement in unrestricted quantities. A revised list has been posted on the dedicated website for CAFTA-DR Commercial Availability proceedings, at https://otexaprod.trade.gov/otexacapublicsite/shortsupply/cafta.

HTS: 5407.52.20.40; 5407.72.00.15

Fabric Type: Woven—Double Weave

Fiber Content (AATCC 20A): Polyester 88-92%, Spandex 8-12%

Yarn Size:

Warp Yarn: 45-55 Denier/144 Filaments Semi-Dull Texturized + 15-25 Denier Spandex Textured Filament

Weft Yarn 1: 45-55 Denier/72 Filaments Semi-Dull Texturized + 15-25 Denier Spandex Textured Filament

Weft Yarn 2: 145-155 Denier/96 Filaments Semi-Dull Texturized

Weave Type: Woven, Double Weave Dobby

Thread Count (ASTM D3775): 66-72 warp ends × 70-78 filling picks

Fabric Weight (g/m2) (ASTM D3776): 159-169 g/m2

Width (cuttable) (ASTM D3774):

Metric: 124.5-139.7 cm

English: 49-55 inches

Stretch (%) (ASTM D3107):

Warp: 20.4% (10%-30%)

Weft: 18% (8%-28%)

Stretch Direction: Four-way stretch

Finish (AATCC 197): Quick Dry (Wicking)

Dye Type: Piece dye of various colors

Shrinkage (AATCC 135): +/− 5%

The prospective exclusive license will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The patent rights in these inventions have been assigned to the United States Government as represented by the National Security Agency.

The Department, in accordance with the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3506(c)(2)(A)), provides the general public and Federal agencies with an opportunity to comment on proposed, revised, and continuing collections of information. This helps the Department assess the impact of its information collection requirements and minimize the public's reporting burden. It also helps the public understand the Department's information collection requirements and provide the requested data in the desired format. The Department is soliciting comments on the proposed information collection request (ICR) that is described below. The Department is especially interested in public comment addressing the following issues: (1) is this collection necessary to the proper functions of the Department; (2) will this information be processed and used in a timely manner; (3) is the estimate of burden accurate; (4) how might the Department enhance the quality, utility, and clarity of the information to be collected; and (5) how might the Department minimize the burden of this collection on the respondents, including through the use of information technology. Please note that written comments received in response to this notice will be considered public records.

Title of Collection: eZ-Audit: Electronic Submission of Financial Statements and Compliance Audits.

OMB Control Number: 1845-0072.

Type of Review: Extension without change of a currently approved ICR.

Respondents/Affected Public: State, Local, and Tribal Governments; Private Sector; Individuals or Households.

Total Estimated Number of Annual Responses: 6,632.

Total Estimated Number of Annual Burden Hours: 6,603.

Abstract: eZ-Audit is a web-based process designed to facilitate the submission of compliance and financial statement audits, expedite the review of those audits by the Department, and provide more timely and useful information to public, non-profit and proprietary institutions regarding the Department's review. eZ-Audit establishes a uniform process under which all institutions submit directly to the Department any audit required under the Title IV, HEA program regulations. eZ-Audit continues to have minimal number of financial template line items and general information questions. There has been no change to the form or method of submission.

The Department, in accordance with the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3506(c)(2)(A)), provides the general public and Federal agencies with an opportunity to comment on proposed, revised, and continuing collections of information. This helps the Department assess the impact of its information collection requirements and minimize the public's reporting burden. It also helps the public understand the Department's information collection requirements and provide the requested data in the desired format. The Department is soliciting comments on the proposed information collection request (ICR) that is described below. The Department is especially interested in public comment addressing the following issues: (1) is this collection necessary to the proper functions of the Department; (2) will this information be processed and used in a timely manner; (3) is the estimate of burden accurate; (4) how might the Department enhance the quality, utility, and clarity of the information to be collected; and (5) how might the Department minimize the burden of this collection on the respondents, including through the use of information technology. Please note that written comments received in response to this notice will be considered public records.

Title of Collection: Campus Safety and Security Survey.

OMB Control Number: 1840-0833.

Type of Review: A revision of a currently approved ICR.

Respondents/Affected Public: Private Sector; State, Local, and Tribal Governments.

Total Estimated Number of Annual Responses: 5,784.

Total Estimated Number of Annual Burden Hours: 2,604.

Abstract: The collection of information through the Campus Safety and Security Survey (CSS) is necessary under section 485 of the Higher Education Act of 1965, as amended, with the goal of increasing transparency surrounding college safety and security information for students, prospective students, parents, employees and the general public. The survey is a collection tool to compile the annual data on campus crime and fire safety. The data collected from the individual institutions by the Department of Education (ED) is made available to the public through the Campus Safety and Security Data Analysis and Cutting Tool as well as the College Navigator. This revision is being submitted to add new collection requirements from the Stop Campus Hazing Act.

Commonwealth states that its upstream ownership changed pursuant to a transation that closed on May 14, 2026 (Transaction) in connection with the Final Investment Decision for the Commonwealth LNG Project. According to Commonwealth, the Canada Pension Plan Investment Board (CPP Investments) acquired a 22.8% equity interest in Commonwealth's corporate parent, Caturus Holdco, LLC (Caturus). 1 Commonwealth states that, before the Transaction, Kimmeridge Energy Management Company, LLC (Kimmeridge) held a 75.9% equity interest in Caturus, and CPP Investments held an indirect interest in Caturus through the Kimmeridge funds in which it invests. Commonwealth adds that, although CPP Investments now holds a 33.1% interest in Commonwealth as a result of the Transaction and its other prior investments in Kimmeridge funds, its ownership interest including governance rights is limited to 22.8%, acquired in the Transaction. Commonwealth further states that Kimmeridge and Mubadala Energy remain equity owners of Caturus, and Caturus remains the 100% indirect owner of Commonwealth.

A chart illustrating the ownership structure of Commonwealth after the Transaction is attached to the Statement as Attachment A. Additional details can be found in the Statement and Clarification, posted on the DOE website at https://www.energy.gov/hgeo/articles/commonwealth-lng-llc-fe-dkt-no-19-134-lng.

DOE will review the Statement in accordance with its CIC Procedures. 2 Consistent with the CIC Procedures, this notice addresses Commonwealth's existing authorization to export domestically produced LNG by vessel to countries with which the United States has not entered into a free trade agreement (FTA) requiring national treatment for trade in natural gas and with which trade is not prohibited by United States law or policy (non-FTA countries), granted in DOE/FECM Order No. 5238-A. 3 If no interested person protests the change in control and DOE takes no action on its own motion, the proposed change in control will be deemed granted 30 days after publication in the Federal Register . If one or more protests are submitted, DOE will review any motions to intervene, protests, and answers, and will issue a determination as to whether the proposed change in control has been demonstrated to render the underlying authorizations inconsistent with the public interest.

Interested persons will be provided 15 days from the date of publication of this notice in the Federal Register to move to intervene, protest, and answer Commonwealth's Statement. 4 Protests, motions to intervene, notices of intervention, and written comments are invited in response to this notice only as to the change in control described in the Statement. All protests, comments, motions to intervene, or notices of intervention must meet the requirements specified by DOE's regulations in 10 CFR part 590, including the service requirements.

Filings may be submitted using one of the following methods:

(1) Submitting the filing electronically at fergas@hq.doe.gov;

(2) Mailing the filing to the Office of Global Energy Security at the address listed in the ADDRESSES section; or

(3) Hand delivering the filing to the Office of Global Energy Security at the address listed in the ADDRESSES section.

For administrative efficiency, DOE prefers filings to be filed electronically. All filings must include a reference to “Docket No. 19-34-LNG” or “Commonwealth Change in Control” in the title line. Filings must be submitted in English to be considered. 5

For electronic submissions: Please include all related documents and attachments ( e.g., exhibits) in the original email correspondence. Please do not include any active hyperlinks or password protection in any of the documents or attachments related to the filing. All electronic filings submitted to DOE must follow these guidelines to ensure that all documents are filed in a timely manner.

The Statement, and any filed protests, motions to intervene, notices of intervention, and comments will be available electronically on the DOE website at www.energy.gov/hgeo/regulation.

Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-3520), federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. The term “collection of information” is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires federal agencies to publish a 30-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension or reinstatement of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, CMS is publishing this notice that summarizes the following proposed collection(s) of information for public comment.

1. Type of Information Collection Request: New collection (Request for a new OMB control number); Title of Information Collection: State Exchange Improper Payment Measurement (SEIPM); Use: The Payment Integrity Information Act of 2019 (PIIA) requires Federal agencies to annually identify, review, measure, and report on the programs they administer that have been determined to be susceptible to significant improper payments. In 2016, HHS determined that payments of APTC are susceptible to significant improper payments and, as a result, are subject to the requirements of PIIA. In accordance with 45 CFR part 155, FFEs, SBE-FPs, and state Exchanges that operate their own eligibility and enrollment systems, determine the amount of APTC to be paid to qualified applicants. Starting in the FY22 Agency Financial Report (AFR), HHS began annually reporting improper payments of APTC administered through FFEs and SBE-FPs as part of the Exchange Improper Payment Measurement (EIPM) program. In 2024, HHS required State Exchanges to participate in the Improper Payment Pre-Testing and Assessment (IPPTA) to prepare State Exchanges for the future implementation of the SEIPM program.

HHS proposes to require state Exchanges to submit to HHS, a sample of tax household information from Qualified Health Plans (QHPs) that have associated APTC payments, for the purpose of being reviewed for improper payments. HHS proposes that the sample size would be of a sufficient quantity to produce a statistically valid estimate of improper payments and in accordance with requirements established by the Office of Management and Budget (OMB). HHS proposes that the measurement of all state Exchanges would occur on an annual basis unless otherwise determined by HHS. The calculated estimate of improper payments would be reported annually in the HHS Agency Financial Report (AFR) as an aggregate rate across all state Exchanges. At HHS' discretion, contractors would be used to support these activities. The burden associated with completion and return of the proposed required information will be the time it will take each state Exchange to meet with HHS to review the information. We estimate that the burden associated with this data collection and transfer will be no more than 8 hours for each sample collected. Form Number: CMS-10942 (OMB control number: 0938-NEW); Frequency: Annually; Affected Public: State, Local, or Tribal Governments; Number of Respondents: 20; Total Annual Responses: 20; Total Annual Hours: 800. (For policy questions regarding this collection contact Halina DeSantis at halina.desantis@cms.hhs.gov. )

2. Type of Information Collection Request: Revision of currently approved collection; Title of Information Collection: Consumer Experience Survey Data Collection; Use: Section 1311(c)(4) of the Affordable Care Act requires the Department of Health and Human Services (HHS) to develop an enrollee satisfaction survey system that assesses consumer experience with qualified health plans (QHPs) offered through an Exchange. It also requires public display of enrollee satisfaction information by the Exchange to allow individuals to easily compare enrollee satisfaction levels between comparable plans. HHS established the QHP Enrollee Experience Survey (QHP Enrollee Survey) to assess consumer experience with the QHPs offered through the Marketplaces. The survey includes topics to assess consumer experience with the health care system such as communication with providers and ease of access to health care services.

CMS developed the survey using the Consumer Assessment of Health Providers and Systems (CAHPS®) principles ( https://www.ahrq.gov/cahps/about-cahps/principles/index.html ) and established an application and approval process for survey vendors who want to participate in collecting QHP enrollee experience data. The QHP Enrollee Survey, which is based on the CAHPS® Health Plan Survey, will be used to (1) help consumers choose among competing health plans, (2) provide actionable information that the QHPs can use to improve performance, (3) provide information that regulatory and accreditation organizations can use to regulate and accredit plans, and (4) provide a longitudinal database for consumer research. To develop the QHP Enrollee Survey, CMS completed developmental testing, including psychometric testing and beta testing. Additional changes made the survey since its development have been informed by focus groups with consumers and QHP issuers, cognitive testing with consumers, and input CMS received from interested parties. CMS previously obtained clearance for the 2016-2026 administrations of the QHP Enrollee Survey. At this time, CMS is requesting to renew approval for the information collection related to the QHP Enrollee Experience Survey in 2027-2029. These activities are necessary to ensure that CMS fulfills legislative mandates established by section 1311(c)(4) of the Affordable Care Act to develop an “enrollee satisfaction survey system” and provide such information on Marketplace websites. CMS is also seeking approval to revise the QHP Enrollee Survey beginning with 2027 to improve response rates, reduce burden on QHP enrollees and improve overall instrument alignment with the Consumer Assessment of Healthcare Providers and Systems (CAHPS) 5.1 Survey. To accomplish this, CMS is proposing to remove four questions related to tobacco-usage that are used to calculate the Medical Assistance with Smoking and Tobacco Use Cessation measure. CMS is also proposing to replace the two demographic questions related to race and ethnicity with one question aligned with the Office of Management and Budget (OMB) Revisions to OMB's Statistical Policy Directive No. 15: Standards for Maintaining, Collecting, and Presenting Federal Data on Race and Ethnicity. CMS is further proposing to refine the survey instrument to align questions related to telehealth with the CAHPS 5.1 Survey. CMS is also proposing to add 5 gate questions to allow participants to screen out of detailed follow-up questions that do not apply to them (see the Crosswalk of Changes to the QHP Enrollee Survey). CMS proposes allowing the customization of the mail and internet survey instruments to replace “Qualified Health Plan (QHP)” with the QHP issuer's name on the cover page. CMS is also proposing to update the QHP Enrollee Survey sampling protocol to allow oversampling at any level. CMS is also seeking to add a third email reminder on Day 40 of the fielding timeline and to extend the telephone dialing period by one week to begin on Day 48 of the fielding timeline. Finally, CMS is proposing revisions to the survey instrument, prenotification letter, reminder letter, survey cover letter, and notification/reminder emails for plain language to reduce repetition and improve readability. Form Number: CMS-10488 (OMB control number: 0938-1221); Frequency: Annually; Affected Public Sector: (Individuals and Households), Private sector (Business or other for-profits and Not-for-profit institutions); Number of Respondents: 72,008 respondents; Total Annual Responses: 72,008; Total Annual Hours: 12,013. (For policy questions regarding this collection contact Preeti Hans 301-492-5114).

FDA is responsible under the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 301 et seq. ) and the Public Health Service Act for protecting and promoting the public health through the regulation of human drugs, biological products, medical devices, foods, and other products. FDA's oversight of drug products, including potential psychedelic drug products, spans preclinical investigation through the full lifecycle of an approved product. FDA remains committed to advancing innovation while upholding its public health mission to ensure that drugs are safe, effective, and of high quality. With respect to psychedelic drug development, FDA has made significant advances.

In April 2026, FDA issued national priority vouchers to companies studying psilocybin for treatment-resistant depression (TRD), psilocybin for major depressive disorder (MDD), and methylone for post-traumatic stress disorder (PTSD) (U.S. Food and Drug Administration, 2026). Through enhanced regulatory engagement and streamlined review procedures, national priority vouchers are designed to significantly reduce review times for qualifying drug applications for products that align with critical U.S. national health priorities, while maintaining FDA's rigorous scientific and regulatory standards.

FDA has also granted Breakthrough Therapy designation to specific psychedelic drug development programs, including MDMA for the treatment of PTSD (Multidisciplinary Association for Psychedelic Studies, 2017) and psilocybin for TRD (COMPASS Pathways, 2018) and MDD (Khan, 2019). Breakthrough Therapy designation facilitates and expedites the development and review of drugs intended to treat a serious or life-threatening disease or condition where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available treatments on a clinically significant endpoint (U.S. Food and Drug Administration, 2018). Neither national priority voucher issuance nor Breakthrough Therapy designation constitutes an FDA determination of safety or effectiveness, and neither is a substitute for marketing approval.

This hearing also supports implementation of Executive Order 14401 of April 18, 2026, “Accelerating Medical Treatments for Serious Mental Illness” (91 FR 21709, April 22, 2026), which establishes a policy of accelerating innovative research models and appropriate drug approvals to help increase access to psychedelic drugs for serious mental illness, and which directs HHS and FDA to collaborate with other federal departments and agencies, as appropriate and consistent with applicable law, to increase clinical trial participation, data sharing, and real-world evidence generation regarding psychedelic drugs.

Given this background, and as part of that coordinated federal effort, FDA and federal partners seek input on considerations for the potential future therapeutic use of psychedelic drugs in supervised and supportive settings.

FDA will hold a public hearing consistent with 21 CFR part 15 (part 15) to provide the opportunity for the public to present information and views on the potential future therapeutic use of psychedelic drugs in supervised and supportive settings. The hearing will be conducted by a presiding officer, who will be accompanied by FDA panelists, including subject matter experts from the Center for Drug Evaluation and Research, as well as federal partner panelists. As provided in § 15.30(f) (21 CFR 15.30(f)), the hearing is informal, and the rules of evidence do not apply. No participant may interrupt the presentation of another participant. Only the presiding officer and panel members may pose questions; they may question any person during or at the conclusion of each presentation.

Public hearings under part 15 are subject to FDA's policy and procedures for electronic media coverage of FDA's public administrative proceedings (21 CFR part 10, subpart C). Under 21 CFR 10.205, representatives of the media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA's public administrative proceedings, including presentations by participants. The hearing will be transcribed as provided in § 15.30(b) (see also TRANSCRIPTS). To the extent that the conditions for the hearing, as described in this notice, conflict with any provisions set out in part 15, this notice acts as a waiver of those provisions as specified in § 15.30(h).

FDA and our federal partners are interested in public input on the potential future therapeutic use of psychedelic drugs in supervised and supportive settings, including the following topics: (1) provider training and credentialing, (2) promotion of patient safety, (3) considerations for access, and (4) best practices for data collection and standardization.

Certain topics identified below implicate the authorities of other federal agencies or of states; FDA seeks this input to inform coordinated consideration and does not intend this notice to suggest FDA regulatory action outside our statutory authority. Input on operational, workforce, and access considerations may also inform understanding of how any measures to promote safe use could affect patient access to, and healthcare system capacity to deliver, these therapies.

○ The evidence base for training and educational curricula, and the expert body(ies), if any, that would be expected to develop, review, or endorse them.

○ Personnel and training needs by phase of care (screening and preparation, administration and monitoring, and follow-up), including minimum staffing during administration and monitoring and the roles and qualifications of non-prescriber personnel such as licensed counselors and peer support specialists.

○ Training for care coordination across primary care, behavioral health, and specialty providers.

○ Credentialing and licensure considerations, ranging from background education and experiential qualifications to supervision and practice hour requirements.

○ Best practices to promote patient safety, including patient education and counseling, assessment of side effects, and considerations of set and setting ( i.e., mindset and environment).

○ Topics that should be explicitly addressed in informed consent procedures, e.g., the potential for an amplified power imbalance between patient and provider, the use of therapeutic touch, and the risk of psychological distress or a challenging psychedelic experience.

○ Recommended practices to screen patients before treatment for medical and psychiatric conditions associated with greater risk of adverse outcomes ( e.g., cardiovascular disease, psychosis, or suicidality).

○ Strategies to mitigate potential diversion and non-medical use of psychedelic drugs, once approved by FDA.

○ Mechanisms to prevent, detect, and report ethical violations by practitioners to appropriate authorities.

○ Criteria for determining appropriate monitoring during and after drug administration, as well as coordination of post-administration follow-up, including with emergency and crisis response services where needed.

○ Evidence needs for coverage, benefit design, reimbursement, and payment models, including healthcare economic impact analyses.

○ Preparation and coordination between providers and payors to enable appropriate access to services.

○ Considerations for implementation of access to services, including workforce, space, scheduling, storage, security, and clinic capacity.

○ Telehealth screening, follow-up, and care coordination.

○ Creation of data repositories ( e.g., Coordinated Registry Networks) that may inform real-world assessment of safety.

○ Data sources and coordination across data sources—including electronic health records, insurance claims, registries, pharmacy data, adverse event reports, patient- and clinician-reported outcomes, national surveillance systems, federally funded surveys, and state programs for psychedelic use—to characterize both medical and non-medical use.

○ Establishment of common data elements across data sources for drug, dosage, indication, setting, and patient characteristics ( e.g., comorbidities).

○ Approaches to defining, identifying, and reporting adverse events in the context of the acute and long-term effects of psychedelic drugs.

○ Considerations for interoperability and linkages across healthcare delivery systems and settings, data quality, privacy-protection, and longitudinal follow-up.

FDA is not seeking comment on the following topics: (1) the safety or effectiveness of any particular drug product, or the merits of any pending or anticipated application before the Agency; (2) the scheduling status of any substance under the Controlled Substances Act, which is addressed through separate statutory processes; (3) the legalization or decriminalization of psychedelic substances, or the merits of state or local programs authorizing their use, although FDA welcomes input on data collection from such programs as described above; (4) religious, ceremonial, or personal (non-medical) use of psychedelic substances; or (5) individual disputes, enforcement matters, or complaints regarding specific practitioners or entities. Comments and presentations addressing these topics may not be considered.

Registration: To register to attend the free public hearing, please visit the following website: www.fda.gov/news-events/fda-meetings-conferences-and-workshops/considerations-potential-future-therapeutic-use-psychedelic-drugs-public-hearing-09142026. Registration will open on July 13, 2026. Live closed captioning will be provided during the public hearing. Additional information on requests for special accommodations due to a disability will be provided during registration.

Requests to Present: During online registration, you may request to present information and views at the hearing. Each request to present must include: (1) the presenter's name, title, affiliation, and contact information; (2) the organizations or interests, if any, on whose behalf the presenter would appear, including disclosure of any financial relationships with entities developing, manufacturing, or expecting to provide products or services related to psychedelic drugs; and (3) the topic area(s) identified in section III that the presentation will address. Individuals and organizations with common interests are urged to consolidate or coordinate their presentations and to designate a single presenter.

FDA anticipates that requests to present will exceed the time available. If so, FDA will select presenters and allot presentation time with the goal of having a broad representation of ideas and issues presented at the meeting. Following the close of registration, FDA will determine the time allotted to each presenter and the approximate start time of each presentation and will notify participants ahead of the hearing. All written requests for participation must be received by August 21, 2026, 11:59 p.m. Eastern Time. No commercial or promotional material will be permitted to be presented or distributed at the public hearing.

Selection to present at the meeting is not a prerequisite for having your views considered. Persons not selected to present, or who prefer not to present, may submit the same information as written or electronic comments to the docket (see ADDRESSES ), and FDA will consider timely written comments equally with oral presentations.

Transcripts: A transcript of the public hearing will be available at https://www.regulations.gov as soon as possible after the hearing and may be viewed at the Dockets Management Staff (see ADDRESSES ). A link to the transcript will also be available at www.fda.gov/news-events/fda-meetings-conferences-and-workshops/considerations-potential-future-therapeutic-use-psychedelic-drugs-public-hearing-09142026.

The following references marked with an asterisk (*) are on display at the Dockets Management Staff (see ADDRESSES ) and are available for viewing by interested persons between 9 a.m. and 4 p.m., Monday through Friday; they also are available electronically at https://www.regulations.gov. FDA has verified the website addresses as of the date this document publishes in the Federal Register , but websites are subject to change over time.

FDA is announcing the availability of a final guidance for industry titled “Formal Meetings Between FDA and Sponsors or Requestors of Over-the-Counter Monograph Drugs.” This guidance provides recommendations to industry on formal meetings between FDA and sponsors or requestors of nonprescription drugs without approved new drug applications that are governed by section 505G of the FD&C Act (21 U.S.C. 355h) (hereafter referred to as OTC monograph drugs) or organizations nominated by sponsors or requestors to represent their interests in a proceeding. For the purposes of this guidance, a formal meeting includes any meeting that is requested by a sponsor or requestor of OTC monograph drugs (hereafter referred to collectively as meeting requester(s)) to obtain advice on the studies and other information necessary to support OTC monograph order submissions, to obtain advice on other matters relevant to OTC monograph drug regulation, or to obtain advice on OTC monograph drug development and includes meetings conducted in any format ( i.e., hybrid in person face-to-face, virtual face-to-face video conference, teleconference, and written response only).

Section 505G of the FD&C Act was added by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), Public Law 116-136, 134 Stat. 281, 457, which was enacted on March 27, 2020. As required by section 505G(l) of the FD&C Act (21 U.S.C. 355l), this guidance discusses the procedures and principles for formal meetings between FDA and meeting requesters. In doing so, and as required by section 505G(h) of the FD&C Act, this guidance describes procedures under which meeting requesters can meet with appropriate FDA officials to obtain advice on the studies and other information necessary to support submissions under section 505G of the FD&C Act, to obtain advice on other matters relevant to the regulation of nonprescription drugs, and to obtain advice on the development of new OTC monograph drugs. This guidance also applies to meetings with FDA to obtain advice on clinical investigations that may be conducted under an investigational new drug application (IND) where the purpose of the IND is to conduct a clinical investigation to support a determination of whether an OTC monograph condition is generally recognized as safe and effective under section 505G(b) of the FD&C Act. As required by section 505G(i) of the FD&C Act, this guidance also describes procedures to facilitate efficient participation in joint meetings by multiple meeting requesters and/or organizations nominated by them to represent their interests.

This guidance does not apply to formal meetings for the development of nonprescription drug products intended for submission in new drug applications or abbreviated new drug applications under section 505 of the FD&C Act.

In support of the CARES Act, FDA agreed to specific performance goals and procedures described in the document “Over-the-Counter Monograph User Fee Program Performance Goals and Procedures—Fiscal Years 2018-2022,” commonly referred to as the OMUFA Commitment Letter (the document can be accessed at https://www.fda.gov/media/106407/download and the document with updated goal dates for fiscal years 2021-2025 can be accessed at https://www.fda.gov/media/146283/download ). In the OMUFA Commitment Letter, FDA committed to issuing this guidance under specific timelines. Under the reauthorization of the Over-the-Counter Monograph User Fee Amendments (OMUFA) (Pub. L. 119-37, 139 Stat. 637), which was enacted on November 12, 2025, FDA continued to agree to specific performance goals and procedures as described in the document “Over-the-Counter Monograph Drug User Fee Program Performance Goals and Procedures—Fiscal Years 2026-2030 document (OMUFA II commitment letter) and to apply them to formal meetings between FDA staff and meeting requesters (the document can be accessed at https://www.fda.gov/media/182750/download ). The OMUFA II commitment letter includes updated meeting management goals for formal meetings that occur between FDA and meeting requesters, which are incorporated into this guidance.

This guidance finalizes the draft guidance titled “Formal Meetings Between FDA and Sponsors or Requestors of Over-the-Counter Monograph Drugs” issued on February 7, 2022 (87 FR 6877). FDA considered comments received on the draft guidance as the guidance was finalized. Changes from the draft guidance to the final guidance are primarily intended to improve clarity and to address comments. On our own initiative, we revised the guidance to apply to meetings with FDA to obtain advice on clinical investigations that may be conducted under an IND, where the purpose of the IND is to conduct a clinical investigation to support a determination of whether there are conditions under which a nonprescription drug is generally recognized as safe and effective. To conform to the OMUFA II commitment letter, FDA also made clarifying revisions to specify the requirements in order to qualify for specific meeting performance goals. For consistency and clarity, FDA clarified the meeting formats. To address commenters' concerns that FDA was limiting the number of Type Y meetings, which could affect OTC monograph order development, we explain that there are three different categories of Type Y meetings and that generally FDA will grant one Type Y meeting per category during the course of the meeting requester's OTC monograph order development program. On our own initiative, we revised the meetings formats ( i.e., in person face-to-face, virtual face-to-face, teleconference, and written response only (WRO)) to better accommodate virtual and hybrid meetings. To address apparent commenter confusion, we removed the use of the term “OTC monograph industry working group” and replaced it with the term “joint meeting requester” to avoid confusion. To address commenter concerns about confidentiality, we clarified when information submitted to FDA in connection with formal meetings is considered confidential and when FDA would post information in connection with a formal meeting. To address commenter questions, we explained the process for meeting requesters to submit clarifying questions on information in the meeting minutes or WRO to FDA following their receipt.

This guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The guidance represents the current thinking of FDA on “Formal Meetings Between FDA and Sponsors or Requestors of Over-the-Counter Monograph Drugs.” It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.

Under section 505G(o) of the FD&C Act, the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-3521) does not apply to collections of information made under section 505G of the FD&C Act. The information collections made in this guidance implement the provisions of three subsections of section 505G: (1) Section 505G(l)(1), which requires FDA to issue guidance that specifies the procedures and principles for formal meetings between FDA and sponsors or requestors for drugs subject to section 505G; (2) section 505G(h), which requires FDA to establish procedures under which meeting requestors can meet with appropriate FDA officials to obtain advice on the studies and other information necessary to support submissions under section 505G, other matters relevant to the regulation of nonprescription drugs, and the development of new nonprescription drugs under section 505G; and (3) section 505G(i), which requires FDA to, among other things, establish procedures to facilitate efficient participation in joint meetings by multiple meeting requesters and/or organizations nominated by them to represent their interests. Therefore, clearance by the Office of Management and Budget under the Paperwork Reduction Act of 1995 is not required for these collections of information.

While this guidance contains no collection of information, it does refer to previously approved FDA collections of information subject to review by the Office of Management and Budget (OMB) under the PRA. The collections of information in 21 CFR 312 for investigational new drug applications have been approved under OMB control number 0910-0014. The collections of information in 21 CFR 201 subpart C for Labeling requirements for Over-the-Counter drugs and submission of OTC monograph fees have been approved under OMB control number 0910-0340. The information collections for OTC meetings and OTC information not exempted from PRA under section 505G of the FD&C Act have been approved under OMB control number 0910-0340.

Persons with access to the internet may obtain the draft guidance at https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs, https://www.fda.gov/regulatory-information/search-fda-guidance-documents, or https://www.regulations.gov.

FDA is announcing the availability of a guidance for industry titled “Topical Dermatologic Corticosteroids: In Vivo Bioequivalence.” This guidance provides recommendations to applicants who submit ANDAs for topical corticosteroids. This guidance describes recommendations for an in vivo pharmacodynamic approach to demonstrate the BE of topical corticosteroids.

This guidance finalizes the draft guidance titled “Topical Dermatologic Corticosteroids: In Vivo Bioequivalence” issued on October 24, 2022 (87 FR 64229), and replaces the final guidance of the same title issued June 2, 1995. FDA considered comments received on the draft guidance as the guidance was finalized. Changes from the draft to the final guidance include clarifications noting that study subjects used for chromameter and operator qualification could differ from those enrolled in the pilot dose duration vasoconstrictor response and pivotal vasoconstrictor BE studies, and the addition of history of hypopigmentation as a subject exclusion criterion. In addition, editorial changes were made to improve clarity.

This guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The guidance represents the current thinking of FDA on “Topical Dermatologic Corticosteroids: In Vivo Bioequivalence.” It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.

While this guidance contains no collection of information, it does refer to previously approved FDA collections of information. The previously approved collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-3521). The collections of information in 21 CFR 314 have been approved under OMB control number 0910-0001. The collections of information pertaining to controlled correspondence related to generic drug development have been approved under OMB control number 0910-0727.

Persons with access to the internet may obtain the guidance at https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs, https://www.fda.gov/regulatory-information/search-fda-guidance-documents, or https://www.regulations.gov.

FDA is announcing the availability of a final guidance for industry titled “Psychedelic Drugs: Considerations for Clinical Investigations.” This final guidance outlines general considerations for drug development programs considering the therapeutic potential of psychedelic drugs for the treatment of medical conditions ( e.g., psychiatric disorders, substance use disorders). This final guidance applies to clinical trials on investigational products and addresses recommendations for study design, including considerations for data collection, data generation, and patient monitoring.

This guidance finalizes the draft guidance of the same title issued on June 26, 2023 (88 FR 41407). FDA considered docket comments received in response to the draft guidance as part of this revision. To enhance clarity, a few revisions were made in this revised version.

This guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The guidance represents the current thinking of FDA on “Psychedelic Drugs: Considerations for Clinical Investigations.” It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.

FDA considered the applicability of Executive Order 14192, per OMB guidance in M-25-20, and finds this action to be neither regulatory nor deregulatory.

While this guidance contains no collection of information, it does refer to previously approved FDA collections of information. The previously approved collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-3521). The collections of information relating to the protection of human subjects and institutional review boards in 21 CFR parts 50 and 56 have been approved under OMB control number 0910-0130. The collections of information in 21 CFR parts 210 and 211 relating to current good manufacturing practice requirements for drugs and biologics have been approved under OMB control number 0910-0139. The collections of information in 21 CFR part 312 relating to the investigational new drug applications pathway, which includes clinical trials and clinical trial design, the submission of chemistry, manufacturing and controls information, study protocols, and pharmacological and toxicology information under 21 CFR 312.23, and IND safety reports under 21 CFR 312.32, as well as related meetings between sponsors or applicants and FDA or other communication with appropriate FDA officials to obtain advice on the studies and other information necessary to support submissions, have been approved under OMB control number 0910-0014. The collections of information in 21 CFR part 314 relating to the submission of new drug applications, including the submission of data from a clinical study or studies under 21 CFR 314.50(d)(5) and risk evaluation and mitigation strategies, as well as related meetings between sponsors or applicants and FDA or other communication with appropriate FDA officials to obtain advice on the studies and other information necessary to support submissions, have been approved under OMB control number 0910-0001. In addition, the guidance recommends the use of questionnaires to assess clinical trial subjects' expectations about potential drug effects and at the end of treatment to improve data interpretability. The collection of information from “individuals under treatment or clinical examination in connection with research or prophylaxis to prevent a clinical disorder, [or] direct treatment of that disorder . . .” is not subject to review by OMB under 5 CFR 1320.3(h)(5).

Persons with access to the internet may obtain the guidance at https:// www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs, https://www.fda.gov/regulatory-information/search-fda-guidance-documents, or https://www.regulations.gov.

Inspection of Public Comments: All comments received before the close of the comment period are available for viewing by the public, including any personally identifiable or confidential business information that is included in a comment. All comments received before the close of the comment period will be posted on the following website as soon as possible after they have been received: http://www.regulations.gov. HRSA will not post on Regulations.gov public comments that make threats to individuals or institutions or suggest that the commenter will take actions to harm an individual. HRSA continues to encourage individuals not to submit duplicative comments. HRSA will post acceptable comments from multiple unique commenters even if the content is identical or nearly identical to other comments. HRSA encourages commenters to include supporting facts, research, and evidence in their comments. When doing so, commenters are encouraged to provide citations to the materials referenced, including active hyperlinks. Likewise, commenters who reference materials that have not been published are encouraged to upload relevant data collection instruments, data sets, and detailed findings as a part of their comment. Providing such citations and documentation will assist HRSA in analyzing the comments.

On April 18, 2026, President Trump issued Executive Order (E.O.) 14401, “Accelerating Medical Treatments for Serious Mental Illness”, acknowledging that individuals suffering from serious mental illness may not always respond to existing therapies, and emphasizing the importance of exploring psychedelic therapies as new treatment options. This RFI solicits stakeholder feedback on recommended training and care delivery models that could be used to ensure safe and effective delivery of any potential future FDA-approved psychedelic drugs. In particular, HRSA has interest in ensuring that patients in medically underserved communities have access to these therapies, if approved, and request stakeholder feedback on how psychedelics might be delivered in these settings, including ambulatory clinics such as health centers. HRSA also requests input on workforce training in psychedelic care delivery.

While HRSA accepts all relevant input, we are specifically inviting responses on the following topics, noting this RFI does not necessarily solicit comments on the full scope of topics related to psychedelic therapy. When responding, please provide clear explanations along with detailed responses, including protocols, publications, data and any other relevant materials that may assist HRSA in this RFI.

HRSA recognizes that clinical delivery of psychedelic therapies in health care delivery sites must start with counseling and identification of appropriate patients for such therapies prior to administration of the drug. There also must be appropriate follow up in place following the administration of a psychedelic drug. Although these phases may not be mutually exclusive or entirely distinct, for the purposes of the RFI we are asking questions about training requirements in each of these three phases:

• Pre-administration patient eligibility, screening and counseling: What training should be required of providers counseling, screening, and identifying patients eligible for psychedelic therapy? Should a broad screening process and a more detailed diagnostic assessment be conducted as two separate activities (and if so, provided by different individuals) or combined into a single screening session? What competencies do providers need to achieve to serve patients in this phase of care? Should providers be required to have a professional degree (social work, psychologist, other)? Should providers be required to have a medical degree (physician, nurse practitioner, physician assistant, nurse, other), or not (peers or other trained non-professionals)? Is telehealth an appropriate means of screening and identifying patients for these therapies, and counseling patients on what to expect during psychedelic administration? How do multiple providers ( e.g., primary care and behavioral health providers) communicate plans for psychedelic therapies and/or collaborate to provide psychedelic therapies?

• In-clinic day of drug administration: What training should be required of providers administering psychedelic therapies in an ambulatory clinic setting? What competencies do providers need to achieve to serve patients in this phase of care? Should providers be required to have a professional degree (social work, psychologist, other), or not (peers or other trained non-professionals)? Should providers be required to have a medical degree (physician, nurse practitioner, physician assistant, nurse, other)? Is there a need for a state licensing requirement for providers? Is telehealth and/or remote monitoring an acceptable means of caring for patients during drug administration and observation in clinic?

• Post-administration follow up: What training should be required of providers caring for patients in follow up of psychedelic administration in the days and weeks that follow? Should providers have specialized training in evidence-based psychotherapy keyed to the specific intervention administered? Should providers be required to have a professional degree (social work, psychologist, other), or not (peers or other trained non-professionals)? Should providers be required to have a medical degree (physician, nurse practitioner, physician assistant, nurse, other)? Is telehealth an appropriate means of conducting follow-up?

• General training/supervision: What training models would be most effective ( e.g., didactic, simulation-based, supervised practicum, apprenticeship, certification)? How should supervision requirements differ across provider types, if any?

Patients living in medically underserved communities often have disparate access to new therapies, and improving access to future FDA-approved psychedelic therapies is an Administration priority. HRSA is exploring how HRSA can provide technical assistance and guidance to assist Federally Qualified Health Centers, Certified Community Behavioral Health Clinics, and Rural Health Clinics to be able to safely and effectively administer psychedelic therapies in order to reach medically underserved populations. To understand what may be needed in such settings, HRSA requests responses to the following:

• What should be the basic (essential) requirements for safe administration of psychedelic therapies in ambulatory clinic settings, like health centers?

• What are the ideal environmental and situational features desired in a clinic setting to optimize therapeutic outcomes? Which of these features are essential, and which are more “nice to have”?

• Should a licensed medical provider (physician, nurse practitioner, physician assistant, etc.) medically evaluate a patient prior to drug administration? Should a medical provider be available on site during a psychedelic treatment session?

• How many trained providers should be physically present on-site per patient receiving psychedelic therapy?

• Is telehealth or remote (off-site) monitoring an acceptable model for psychedelic drug therapy, either alone or in combination with an on-site provider?

• Should health centers be required to achieve certification to deliver psychedelic drugs?

• Should requirements be different for different formulations?

• How might implementation of the care delivery model affect workforce productivity and clinic capacity?

• What facility, storage, security, and inventory-control requirements would be necessary for health centers to satisfy legal requirements and to safely receive, store, manage, and administer psychedelic medications, and what challenges would health centers face in meeting those requirements?

• How should clinic organization or operations be adapted to provide psychedelic therapies?

The labor-intensive nature of psychedelic therapy poses a significant challenge to scaling these therapies in medically underserved communities, where workforce shortages are most acute. HRSA is interested in whether and how artificial intelligence (AI), digital health tools, and other technologies might safely expand access and capacity without compromising patient safety. HRSA seeks information related to the following:

• Could tools, including AI technology, support patient screening, eligibility determination, risk stratification, or detection of contraindications? What human oversight should be required, and what are the limits of automated screening for this population?

• Could AI-enabled monitoring ( e.g., automated detection of physiological or behavioral signs of distress) augment or partially substitute for continuous in-person observation during administration, and under what conditions? What safeguards would be essential, recognizing that patients may be acutely vulnerable and unable to self-advocate?

• Could AI-supported tools ( e.g., integration aids, symptom tracking, conversational support) extend clinician-led follow up and integration?

• Could AI and simulation-based tools ( e.g., virtual standardized patients, scenario-based training) accelerate or standardize workforce training, particularly in rural and medically underserved settings?

• Which technology-enabled models offer the greatest potential to expand access in health centers, Certified Community Behavioral Health Clinics, and Rural Health Clinics while maintaining safety, and could they widen or narrow existing disparities?

Please note, this is an RFI only. In accordance with the implementing regulations of the Paperwork Reduction Act of 1995 (PRA), specifically 5 CFR 1320.3(h)(4), this general solicitation is exempt from the PRA. Facts or opinions submitted in response to general solicitations of comments from the public, published in the Federal Register or other publications, regardless of the form or format thereof, provided that no person is required to supply specific information pertaining to the commenter, other than that necessary for self-identification, as a condition of the agency's full consideration, are not generally considered information collections and therefore not subject to the PRA.

This RFI is issued solely for information and planning purposes; it does not constitute a request for proposals, applications, proposal abstracts, or quotations. This RFI does not commit the U.S. Government to contract for any supplies or services or make a grant award. Further, HRSA is not seeking proposals through this RFI and will not accept unsolicited proposals. Respondents are advised that the U.S. Government will not pay for any information or administrative costs incurred in response to this RFI; all costs associated with responding to this RFI will be solely at the interested party's expense. In addition, HRSA will not respond to questions related to policy issues raised in this RFI.

HRSA will actively consider all input as we develop future policy. This RFI should not be construed as a commitment or authorization to incur cost for which reimbursement would be required or sought. All submissions become U.S. Government property and will not be returned. In addition, HRSA shall publicly post the public comments received in their entirety.

The Program provides a system of no-fault compensation for certain individuals who have been injured by specified childhood vaccines. Subtitle 2 of Title XXI of the PHS Act, 42 U.S.C. 300aa-10 et seq., provides that those seeking compensation are to file a petition with the United States Court of Federal Claims and to serve a copy of the petition to the Secretary of HHS, who is named as the respondent in each proceeding. The Secretary has delegated this responsibility under the Program to HRSA. The Court is directed by statute to appoint special masters who take evidence, conduct hearings as appropriate, and make initial decisions as to eligibility for, and amount of, compensation.

A petition may be filed with respect to injuries, disabilities, illnesses, conditions, and deaths resulting from vaccines described in the Vaccine Injury Table (the Table) set forth at 42 CFR 100.3. This Table lists for each covered childhood vaccine the conditions that may lead to compensation and, for each condition, the time period for occurrence of the first symptom or manifestation of onset or of significant aggravation after vaccine administration. Compensation may also be awarded for conditions not listed in the Table and for conditions that are manifested outside the time periods specified in the Table, but only if the petitioner shows that the condition was caused by one of the listed vaccines.

Section 2112(b)(2) of the PHS Act, 42 U.S.C. 300aa-12(b)(2), requires that “[w]ithin 30 days after the Secretary receives service of any petition filed under section 2111 the Secretary shall publish notice of such petition in the Federal Register .” Set forth below is a list of petitions received by HRSA on June 1, 2026, through June 30, 2026. This list provides the name of the petitioner, city, and state of vaccination (if unknown then the city and state of the person or attorney filing the claim), and case number. In cases where the Court has redacted the name of a petitioner and/or the case number, the list reflects such redaction.

Section 2112(b)(2) also provides that the special master “shall afford all interested persons an opportunity to submit relevant, written information” relating to the following:

1. The existence of evidence “that there is not a preponderance of the evidence that the illness, disability, injury, condition, or death described in the petition is due to factors unrelated to the administration of the vaccine described in the petition,” and

2. Any allegation in a petition that the petitioner either:

a. “[S]ustained, or had significantly aggravated, any illness, disability, injury, or condition not set forth in the Vaccine Injury Table but which was caused by” one of the vaccines referred to in the Table, or

b. “[S]ustained, or had significantly aggravated, any illness, disability, injury, or condition set forth in the Vaccine Injury Table the first symptom or manifestation of the onset or significant aggravation of which did not occur within the time period set forth in the Table but which was caused by a vaccine” referred to in the Table.

In accordance with Section 2112(b)(2), all interested persons may submit written information relevant to the issues described above in the case of the petitions listed below. Any person choosing to do so should file an original and three copies of the information with the Clerk of the United States Court of Federal Claims at the address listed above (under the heading For Further Information Contact ), with a copy to HRSA addressed to Director, Division of Injury Compensation Programs, Health Systems Bureau, 5600 Fishers Lane, 8W-25A, Rockville, Maryland 20857. The Court's caption ( Petitioner's Name v. Secretary of HHS ) and the docket number assigned to the petition should be used as the caption for the written submission. Chapter 35 of Title 44, United States Code, related to paperwork reduction, does not apply to information required for purposes of carrying out the Program.

Technology description follows:

Cancer immunotherapy has transformed treatment for some patients, but many tumors still do not respond well to current options, including checkpoint inhibitors. Researchers at NIAID's Laboratory of Immune System Biology (LISB) have developed new antibodies designed to help the immune system fight tumors. These lab-made antibodies, called pan-anti-HLA monoclonal antibodies, block signals that can limit immune cell activity.

These signals are part of a pathway that regulates immune responses. In this pathway, inhibitory receptors in the leukocyte immunoglobulin-like receptor (LILR) family, found on many immune cells like natural killer (NK) cells and T cells, act like a brake when they interact with molecules called MHC-I. The antibodies are designed to block this interaction and release that brake. Earlier studies showed that antibodies targeting this interaction could activate both innate immunity, the body's first line of defense, and adaptive immunity, the part of the immune system that builds more targeted responses and immune memory.

The new pan anti-HLA antibodies 3C10 and 15B1 block LILR interactions by binding to a different site on MHC-I than previously developed antibodies DX17 and W6/32. They also bind more than 50 times better and activate human NK and T cells for tumor control. To support development of next-generation checkpoint therapies, researchers will further evaluate the 3C10 and 15B1 antibodies in animal and tissue-based models.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

Potential Commercial Applications:

• An antibody-based cancer immunotherapy that helps release immune “brakes” on tumor-fighting cells.

• A next-generation checkpoint therapy that could be used alone or with other immunotherapies, including CAR-T or CAR-NK cells.

• A potential immune-based treatment strategy for chronic infections such as TB, HIV, and hepatitis B or C.

Competitive Advantages:

• Target a broad immune “brake” pathway rather than just individual LILR receptors.

• Bind to a different site on MHC-I and does so over 50 times more strongly than earlier antibodies.

• Activates human natural killer (NK) cells and T cells for tumor control.

• Builds on earlier findings showing that blocking this pathway can trigger anti-tumor immune responses.

Development Stage:

• Pre-Clinical.

Inventors: Dr. David Margulies, Dr. Abir Panda, Dr. Ethan Shevach, Dr. Kannan Natarajan, and Ms. Patricia Korty, all of NIAID.

Intellectual Property: HHS Reference No. E-005-2026-0. Provisional Patent Application No. 64/053,946, filed on April 30, 2026.

Licensing Contact: To license this technology, please contact Yogikala Prabhu at 202-365-4785, or yogikala.prabhu@nih.gov, and reference E-005-2026-0.

Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Yogikala Prabhu at 202-365-4785, or yogikala.prabhu@nih.gov.

Under the Refugee Act of 1980 (8 U.S.C. 1522), ORR provides for the effective resettlement of refugees and supports their transition to economic self-sufficiency as quickly as possible. The Act also authorizes the Director to provide RCA and RMA during a defined period not to exceed 36 months following arrival in the United States (8 U.S.C. 1522(e)(1)). RCA and RMA are time-limited benefits available to eligible individuals who do not qualify for certain mainstream assistance programs.

ORR's regulations at 45 CFR 400.211 authorize the Director to determine the appropriate eligibility period for RCA and RMA each fiscal year using a methodology based on factors including available appropriations, and projected arrivals. The regulations also require that any change to the eligibility period currently in effect be announced through publication in the Federal Register (45 CFR 400.211(b)). Prior to 1993, ORR amended its regulations each time it changed the eligibility period. In 1993, ORR revised its approach by removing the specific duration from the regulatory text and establishing a methodology for determining the eligibility period annually (58 FR 64499, Dec. 8, 1993). Under this framework, the methodology is set in regulation, while annual determinations of the eligibility period are issued as interpretive rules.

The eligibility period for RCA and RMA has changed over time in response to funding levels and program needs. Initially, ORR provided these benefits for up to 36 months after arrival. Due to funding constraints, the eligibility period was subsequently reduced to 18 months, then 12 months, and to 8 months in FY 1992. The 8-month eligibility period remained in place for 30 years until FY 2022, when ORR expanded eligibility to 12 months. In FY 2025, ORR reduced the eligibility period to 4 months due to limited funding availability (90 FR 13370, March 31, 2025).

Consistent with regulations, the Director has considered arrival trends, available appropriations, participation rates and projected expenditures in determining the appropriate eligibility period at this time. ORR received a full-year appropriation at the FY 2024 enacted level, resulting in greater available funding than previously anticipated. In addition, actual arrival trends are lower than earlier projections. These factors will allow ORR to increase the months of assistance. But, at the same time, recent legislative changes have limited access to certain government benefits for some ORR-eligible populations, increasing reliance on ORR-funded assistance during the initial resettlement period. These changes are expected to increase participation in ORR benefits, including RMA, as more individuals who might otherwise enroll in other programs, instead access ORR-funded services and thus limits the number of months by which ORR can increase benefits.

In light of these factors, the Director has determined that the RCA and RMA eligibility period will be increased to 8 months. This change will also help ensure that participants have sufficient time to engage in employment services, access needed supports and health services, and move toward economic self-sufficiency, while maintaining the program within available resources. ORR will continue to monitor funding levels, arrival trends, and program needs to ensure that the RCA and RMA eligibility period remains appropriate and sustainable.

ORR-eligible individuals whose eligibility date is on or after January 1, 2026, will be eligible for up to 8 months of RCA and RMA, provided they meet all applicable eligibility requirements under 45 CFR part 400 Subparts E and G. For individuals who received fewer than eight months of RCA or RMA because the eligibility period was previously limited to four months, States or Replacement Designees (RDs) may provide additional months of assistance, up to the eight-month maximum, if the individual remains eligible for benefits at the time the additional assistance is provided. Alternatively, States and RDs may issue retroactive payments for months within the individual's eight-month eligibility period for which assistance was not previously paid, provided the State or RD determines that the individual met all program eligibility requirements during those unpaid months.

Nothing in this notice is intended to allow payment for any month in which an individual did not meet all eligibility requirements in effect for RCA or RMA.

The revised 8-month eligibility period for RCA and RMA is effective on the date of publication of this Federal Register notice. States should begin implementing the expanded RCA and RMA eligibility period as soon as possible and will have up to 30 days to complete any necessary system or operational changes.

On March 1, 2025, the President signed Executive Order (“E.O.”) 14224, Designating English as the Official Language of the United States. See 90 FR 11363 (Mar. 1, 2025). Among other things, E.O. 14224 revoked E.O. 13166, Improving Access to Services for Persons with Limited English Proficiency. See 65 FR 50121 (Aug. 16, 2000); E.O. 14224 (§ 3(b)). E.O. 14224 also directed the Attorney General to “rescind any policy guidance documents issued pursuant to Executive Order 13166 and provide updated guidance, consistent with applicable law.” E.O. 14224, §  3(c).

On July 14, 2025, the Attorney General issued a memorandum providing guidance to federal agencies on appropriate actions to implement E.O. 14224 (“Attorney General Memo”). 1 The Attorney General Memo encouraged all federal agencies to review prior guidance based on E.O. 13166 and rescind such guidance if it conflicts with E.O. 14224 and is not mandated by law or the Constitution.

E.O. 13166 directed “[e]ach agency providing Federal financial assistance shall draft title VI guidance specifically tailored to its recipients that is consistent with the LEP Guidance issued by the Department of Justice,” which were then to be published in the Federal Register for public comment. E.O. 13166 (§  3). Title VI of the Civil Rights Act of 1964, 42 U.S.C. 2000d (Title VI), prohibits discrimination against or otherwise excluding individuals from programs or activities on the basis of race, color, or national origin, if those programs or activities receive federal financial assistance. The Department issued its own agency-specific Title VI language access guidance in 2011. Guidance to Federal Financial Assistance Recipients Regarding Title VI Prohibition Against National Origin Discrimination Affecting Limited English Proficient Persons, 76 FR 21755 (Apr. 18, 2011).

Consistent with E.O. 14224, and the July 14, 2025 Attorney General Memo, the Department is rescinding its 2011 Guidance.

All recipients of DHS financial assistance have a continuing obligation to comply with Title VI, all applicable Title VI regulations, all applicable federal civil rights laws and nondiscrimination provisions. Recipients of federal financial assistance also have a continuing obligation under the Rehabilitation Act of 1973 to ensure that their communications with individuals with disabilities are as effective as communications with others and may need to provide qualified sign language interpreters for individuals who are deaf. Recipients of federal financial assistance, including subrecipients, are reminded that language assistance services may be required under certain circumstances.

DHS anticipates issuing updated language access guidance, consistent with law, as required by E.O. 14224, the July 14, 2025 Attorney General Memo, and future Department of Justice guidance.

The information collection notice was previously published in the Federal Register on May 07, 2026, at 91 FR 24911, allowing for a 60-day public comment period. USCIS did not receive any comments in connection with the 60-day notice.

You may access the information collection instrument with instructions, or additional information by visiting the Federal eRulemaking Portal site at: http://www.regulations.gov and enter USCIS-2008-0010 in the search box. Comments must be submitted in English, or an English translation must be provided. The comments submitted to USCIS via this method are visible to the Office of Management and Budget and comply with the requirements of 5 CFR 1320.12(c). All submissions will be posted, without change, to the Federal eRulemaking Portal at http://www.regulations.gov, and will include any personal information you provide. Therefore, submitting this information makes it public. You may wish to consider limiting the amount of personal information that you provide in any voluntary submission you make to DHS. DHS may withhold information provided in comments from public viewing that it determines may impact the privacy of an individual or is offensive. For additional information, please read the Privacy Act notice that is available via the link in the footer of http://www.regulations.gov.

Written comments and suggestions from the public and affected agencies should address one or more of the following four points:

(1) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(2) Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

(3) Enhance the quality, utility, and clarity of the information to be collected; and

(4) Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

(1) Type of Information Collection Request: Extension, Without Change, of a Currently Approved Collection.

(2) Title of the Form/Collection: Request for the Return of Original Documents.

(3) Agency form number, if any, and the applicable component of the DHS sponsoring the collection: G-884; USCIS.

(4) Affected public who will be asked or required to respond, as well as a brief abstract: Primary: Individuals or households. This form standardizes the USCIS procedures for requesting the return of original documents contained in alien files. The information provided will be used by the USCIS to determine whether a person is eligible to obtain original documents contained in an alien file.

(5) An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond: The estimated total number of annual respondents for the information collection G-884 is 6,600 and the estimated hour burden per response is 0.5 hours.

(6) An estimate of the total public burden (in hours) associated with the collection: The estimated total annual hour burden associated with this collection is 3,300 hours.

(7) An estimate of the total public burden (in cost) associated with the collection: The estimated total annual cost burden associated with this collection of information is $808,500.

The Indian Gaming Regulatory Act of 1988, 25 U.S.C. 2701 et seq., (IGRA) provides the Secretary of the Interior (Secretary) with 45 days to review and approve or disapprove the Tribal-State compact governing the conduct of class III gaming activity on the Tribe's Indian lands. See 25 U.S.C. 2710(d)(8). If the Secretary does not approve or disapprove a Tribal-State compact within the 45 days, IGRA provides the Tribal-State compact is considered to have been approved by the Secretary, but only to the extent the compact is consistent with IGRA. See 25 U.S.C. 2710(d)(8)(D). The IGRA also requires the Secretary to publish in the Federal Register notice of the approved Tribal-State compacts for the purpose of engaging in class III gaming activities on Indian lands. See 25 U.S.C. 2710(d)(8)(D). As required by 25 CFR 293.4, all compacts and amendments are subject to review and approval by the Secretary. The Compact authorizes class III gaming on the Tribe's Indian lands in the State of Kansas, including sports wagering and a hub-and-spoke betting model that deems sports wagers placed anywhere in the State occur on the Tribe's Indian lands where the servers are located, provided the wager is not placed on another Tribe's Indian lands. The Secretary took no action on the Compact within the 45-day statutory review period. Therefore, the Compact is considered to have been approved, but only to the extent it is consistent with IGRA. See 25 U.S.C. 2710(d)(8)(C).

Please refer to Docket ID NRC-2026-3037, facility name, unit number(s), docket number(s), application date, and subject when contacting the NRC about the availability of information for this action. You may obtain publicly available information related to this action by any of the following methods:

• Federal Rulemaking Website: Go to https://www.regulations.gov and search for Docket ID NRC-2026-3037.

• NRC's Agencywide Documents Access and Management System (ADAMS): You may obtain publicly available documents online in the ADAMS Public Documents collection at https://www.nrc.gov/reading-rm/adams.html. To begin the search, select “Begin ADAMS Public Search.” For problems with ADAMS, please contact the NRC's Public Document Room (PDR) reference staff at 1-800-397-4209, at 301-415-4737, or by email to PDR.Resource@nrc.gov. The ADAMS accession number for each document referenced (if it is available in ADAMS) is provided the first time that it is mentioned in this document.

• NRC's PDR: The PDR, where you may examine and order copies of publicly available documents, is open by appointment. To make an appointment to visit the PDR, please send an email to PDR.Resource@nrc.gov or call 1-800-397-4209 or 301-415-4737, between 8 a.m. and 4 p.m. Eastern Time (ET), Monday through Friday, except Federal holidays.

The NRC encourages electronic comment submission through the Federal rulemaking website ( https://www.regulations.gov ). Please include Docket ID NRC-2026-3037, facility name, unit number(s), docket number(s), application date, and subject in your comment submission.

The NRC cautions you not to include identifying or contact information that you do not want to be publicly disclosed in your comment submission. The NRC will post all comment submissions at https://www.regulations.gov as well as enter the comment submissions into ADAMS. The NRC does not routinely edit comment submissions to remove identifying or contact information.

If you are requesting or aggregating comments from other persons for submission to the NRC, then you should inform those persons not to include identifying or contact information that they do not want to be publicly disclosed in their comment submission. Your request should state that the NRC does not routinely edit comment submissions to remove such information before making the comment submissions available to the public or entering the comment into ADAMS.

Pursuant to section 189a.(1)-(2) of the Atomic Energy Act of 1954, as amended (the Act), the NRC is publishing this notice. The Act requires the Commission to publish notice of any amendments issued or proposed to be issued and grants the Commission the authority to issue and make immediately effective any amendment to an operating license or combined license, as applicable, upon a determination by the Commission that such amendment involves NSHC, notwithstanding the pendency before the Commission of a request for a hearing from any person.

This notice includes notices of license amendments containing SUNSI.

The Commission has made a proposed determination that the following license amendment request involve NSHC. Under the Commission's regulations in 10 CFR 50.92, this means that operation of the facility in accordance with the proposed amendments would not (1) involve a significant increase in the probability or consequences of an accident previously evaluated, or (2) create the possibility of a new or different kind of accident from any accident previously evaluated, or (3) involve a significant reduction in a margin of safety. The basis for this proposed determination for each license amendment request is shown as follows.

The Commission is seeking public comments on these proposed NSHC determinations. Any comments received within 30 days after the date of publication of this notice will be considered in making any final determination.

Normally, the Commission will not issue the license amendment until the expiration of 60 days after the date of publication of this notice. The Commission may issue any of these license amendments before expiration of the 60-day period provided that its final determination is that the amendment involves no significant hazards consideration. In addition, the Commission may issue the amendments prior to the expiration of the 30-day comment period if circumstances change during the 30-day comment period such that failure to act in a timely way would result, for example, in derating or shutdown of the facility. If the Commission takes action on any of these license amendments prior to the expiration of either the comment period or the notice period, it will publish a notice of issuance in the Federal Register . If the Commission makes a final no significant hazards consideration determination for any of these license amendments, any hearing on those amendments will take place after issuance. The Commission expects that the need to take this action will occur very infrequently.

Within 60 days after the date of publication of this notice, any person (petitioner) whose interest may be affected by any of these actions may file a request for a hearing and petition for leave to intervene (petition) with respect to that action. Petitions shall be filed in accordance with the Commission's “Agency Rules of Practice and Procedure,” in 10 CFR part 2. Interested persons should consult 10 CFR 2.309. If a petition is filed, the Commission or a presiding officer will rule on the petition and, if appropriate, a notice of a hearing will be issued.

Petitions must be filed no later than 60 days from the date of publication of this notice in accordance with the filing instructions in the “Electronic Submissions (E-Filing)” section of this document. Petitions and motions for leave to file new or amended contentions that are filed after the deadline will not be entertained absent a determination by the presiding officer that the filing demonstrates good cause by satisfying the three factors in 10 CFR 2.309(c)(1)(i) through (iii).

If a hearing is requested, and the Commission has not made a final determination on the issue of NSHC, the Commission will make a final determination on the issue of NSHC, which will serve to establish when the hearing is held. If the final determination is that the license amendment request involves NSHC, the Commission may issue the amendment and make it immediately effective, notwithstanding the request for a hearing. Any hearing would take place after issuance of the amendment. If the final determination is that the license amendment request involves a significant hazards consideration, then any hearing held would take place before the issuance of the amendment unless the Commission finds an imminent danger to the health or safety of the public, in which case it will issue an appropriate order or rule under 10 CFR part 2.

A State, local governmental body, Federally recognized Indian Tribe, or designated agency thereof, may submit a petition to the Commission to participate as a party under 10 CFR 2.309(h) no later than 60 days from the date of publication of this notice. Alternatively, a State, local governmental body, Federally recognized Indian Tribe, or designated agency thereof, may participate as a non-party under 10 CFR 2.315(c).

For information about filing a petition and about participation by a person not a party under 10 CFR 2.315, see ADAMS Accession No. ML20340A053 ( https://adamswebsearch2.nrc.gov/webSearch2/main.jsp?AccessionNumber=ML20340A053 ) and the NRC's public website ( https://www.nrc.gov/about-nrc/regulatory/adjudicatory/hearing.html#participate ).

All documents filed in NRC adjudicatory proceedings, including documents filed by an interested State, local governmental body, Federally recognized Indian Tribe, or designated agency thereof that requests to participate under 10 CFR 2.315(c), must be filed in accordance with 10 CFR 2.302. The E-Filing process requires participants to submit and serve all adjudicatory documents over the internet, or in some cases, to mail copies on electronic storage media, unless an exemption permitting an alternative filing method, as further discussed, is granted. Detailed guidance on electronic submissions is located in the “Guidance for Electronic Submissions to the NRC” (ADAMS Accession No. ML13031A056), and on the NRC's public website ( https://www.nrc.gov/site-help/e-submittals.html ).

To comply with the procedural requirements of E-Filing, at least 10 days prior to the filing deadline, the participant should contact the Office of the Secretary by email at Hearing.Docket@nrc.gov, or by telephone at 301-415-1677, to: (1) request a digital identification (ID) certificate which allows the participant (or their counsel or representative) to digitally sign submissions and access the E-Filing system for any proceeding in which it is participating; and (2) advise the Secretary that the participant will be submitting a petition or other adjudicatory document (even in instances in which the participant, or their counsel or representative, already holds an NRC-issued digital ID certificate). Based upon this information, the Secretary will establish an electronic docket for the proceeding if the Secretary has not already established an electronic docket.

Information about applying for a digital ID certificate is available on the NRC's public website ( https://www.nrc.gov/site-help/e-submittals/getting-started.html ). After a digital ID certificate is obtained and a docket is created, the participant must submit adjudicatory documents in the Portable Document Format. Guidance on submissions is available on the NRC's public website ( https://www.nrc.gov/site-help/electronic-sub-ref-mat.html ). A filing is considered complete at the time the document is submitted through the NRC's E-Filing system. To be timely, an electronic filing must be submitted to the E-Filing system no later than 11:59 p.m. ET on the due date. Upon receipt of a transmission, the E-Filing system time-stamps the document and sends the submitter an email confirming receipt of the document. The E-Filing system also distributes an email that provides access to the document to the NRC's Office of the General Counsel and any others who have advised the Office of the Secretary that they wish to participate in the proceeding, so that the filer need not serve the document on those participants separately. Therefore, applicants and other participants (or their counsel or representative) must apply for and receive a digital ID certificate before adjudicatory documents are filed in order to obtain access to the documents via the E-Filing system.

A person filing electronically using the NRC's adjudicatory E-Filing system may seek assistance by contacting the NRC's Electronic Filing Help Desk through the “Contact Us” link located on the NRC's public website ( https://www.nrc.gov/site-help/e-submittals.html ), by email to MSHD.Resource@nrc.gov, or by a toll-free call at 1-866-672-7640. The NRC Electronic Filing Help Desk is available between 9 a.m. and 6 p.m., ET, Monday through Friday, except Federal holidays.

Participants who believe that they have good cause for not submitting documents electronically must file an exemption request, in accordance with 10 CFR 2.302(g), with their initial paper filing stating why there is good cause for not filing electronically and requesting authorization to continue to submit documents in paper format. Such filings must be submitted in accordance with 10 CFR 2.302(b)-(d). Participants filing adjudicatory documents in this manner are responsible for serving their documents on all other participants. Participants granted an exemption under 10 CFR 2.302(g)(2) must still meet the electronic formatting requirement in 10 CFR 2.302(g)(1), unless the participant also seeks and is granted an exemption from 10 CFR 2.302(g)(1).

Documents submitted in adjudicatory proceedings will appear in the NRC's electronic hearing docket, which is publicly available on the NRC's public website ( https://adams.nrc.gov/ehd ), unless otherwise excluded pursuant to an order of the presiding officer. If you do not have an NRC-issued digital ID certificate as previously described, click “cancel” when the link requests certificates and you will be automatically directed to the NRC's electronic hearing docket where you will be able to access any publicly available documents in a particular hearing docket. Participants are requested not to include personal privacy information such as social security numbers, home addresses, or personal phone numbers in their filings unless an NRC regulation or other law requires submission of such information. With respect to copyrighted works, except for limited excerpts that serve the purpose of the adjudicatory filings and would constitute a Fair Use application, participants should not include copyrighted materials in their submission.

The following table provides the plant name, docket numbers, date of application, ADAMS accession number, and location in the application of the licensee's proposed NSHC determination. For further details with respect to these license amendment applications, see the applications for amendment, publicly available portions of which are available for public inspection in ADAMS. For additional direction on accessing information related to this document, see the “Obtaining Information and Submitting Comments” section of this document.

Pursuant to 39 CFR 3041.405, the Commission gives notice that the Postal Service filed request(s) for the Commission to consider matters related to Competitive negotiated service agreement(s). The request(s) may propose the addition of a negotiated service agreement from the Competitive product list or the modification of an existing product currently appearing on the Competitive product list.

The public portions of the Postal Service's request(s) can be accessed via the Commission's website ( http://www.prc.gov ). Non-public portions of the Postal Service's request(s), if any, can be accessed through compliance with the requirements of 39 CFR 3011.301. 1

Section II identifies the docket number(s) associated with each Postal Service request, if any, that will be reviewed in a public proceeding as defined by 39 CFR 3010.101(p), the title of each such request, the request's acceptance date, and the authority cited by the Postal Service for each request. For each such request, the Commission appoints an officer of the Commission to represent the interests of the general public in the proceeding, pursuant to 39 U.S.C. 505 and 39 CFR 3000.114 (Public Representative). The Public Representative does not represent any individual person, entity or particular point of view, and, when Commission attorneys are appointed, no attorney-client relationship is established. Section II also establishes comment deadline(s) pertaining to each such request.

The Commission invites comments on whether the Postal Service's request(s) identified in Section II, if any, are consistent with the policies of title 39. Applicable statutory and regulatory requirements include 39 U.S.C. 3632, 39 U.S.C. 3633, 39 U.S.C. 3642, 39 CFR part 3035, and 39 CFR part 3041. Comment deadline(s) for each such request, if any, appear in Section II.

Section III identifies the docket number(s) associated with each Postal Service request, if any, to add a standardized distinct product to the Competitive product list or to amend a standardized distinct product, the title of each such request, the request's acceptance date, and the authority cited by the Postal Service for each request. Standardized distinct products are negotiated service agreements that are variations of one or more Competitive products, and for which financial models, minimum rates, and classification criteria have undergone advance Commission review. See 39 CFR 3041.110(n); 39 CFR 3041.205(a). Such requests are reviewed in summary proceedings pursuant to 39 CFR 3041.325(c)(2) and 39 CFR 3041.505(f)(1). Pursuant to 39 CFR 3041.405(c)-(d), the Commission does not appoint a Public Representative or request public comment in proceedings to review such requests.

This Notice will be published in the Federal Register .

For Applicants' representations, legal analysis, and conditions, please refer to Applicants' application, dated May 26, 2026, which may be obtained via the Commission's website by searching for the file number at the top of this document, or for an Applicant using the Company name search field on the SEC's EDGAR system. The SEC's EDGAR system may be searched at https://www.sec.gov/search-filings . You may also call the SEC's Office of Investor Education and Assistance at (202) 551-8090.

For Applicants' representations, legal analysis, and conditions, please refer to Applicants' application, dated May 18, 2026, which may be obtained via the Commission's website by searching for the file number at the top of this document, or for an Applicant using the Company name search field on the SEC's EDGAR system. The SEC's EDGAR system may be searched at https://www.sec.gov/search-filings. You may also call the SEC's Office of Investor Education and Assistance (202) 551-8090.